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              Hepatitis C virus infection (HCV) is emerging as the world’s 
predominant cause of chronic liver disease. Variable prevalence of 
hepatitis C (HCV) infection has been reported in adult patients with 
chronic renal failure on renal replacement therapy. So we have 
studied the prevalence of anti- HCV infection in children in the  renal 
units.  
The objectives of this study were to determine the prevalence 
of anti-HCV antibodies in patients with chronic renal failure, then to 
study the risk factors for acquiring HCV infection and to correlate the 
presence of anti-HCV antibodies to liver disease activity.   
Records were reviewed for demograghic, clinical, biochemical 
data and risk factors .Sera from 50 patients under going 
haemodialysis, peritoneal  or conservative management and 50 
control were tested for antibody to HCV by 3rd generation  Enzyme – 
linked immunosorbent assay.       From a total of 50 patients (33 male 
and 17 female), aged 0-18 yrs, two were anti-HCV positive (4.0%) All 
the anti-HCV positive patients had been on haemodialysis for a mean 
of 27 months, while the anti- HCV negative patients had been on 
dialysis for 15 months (p<0.003). 
All the anti-HCV positive patients had been transfused with 2-8 
units, a mean of  5 units  (p<0.000). No one of them has had prior or 
recent HBV or HIV infection.  
The most predictive risk factor for HCV infection was the length 
of time on haemodialysis.Three out of the 50 patients had high 
alanine amino transferase levels. Two were patients with chronic 
renal failure; one of them was positive while the other was negative 
for anti-HCV, the third one was in the control group with negative anti-
HCV. 
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1.  INTRODUCTION AND LITERATURE REVIEW 
1. Chronic renal failure 
1.1. Historical background 
  During the late 1970s, whether any child was candidate for 
any form of renal replacement therapy was questioned because the 
risk of therapy was not thought to justify the potential benefit.  Since 
that time, dialysis followed by renal transplantation became routine 
therapy for treatment of children with end-stage renal disease 
ESRD.(1) 
1.2. Incidence 
 The incidence of chronic renal disease in children is steadily 
increase in US followed by Japan. Current data suggest that 1.5 to 
3.0 children per one million populations per year develop ESRD. 
The North American Pediatric Renal Transplant Cooperative Study 
Group (NAPRTCS) initiated a registry of children treated with 
dialysis; 2, 828 patients had been registered.  NAPRTCS initiated a 
registry to collect data from children with chronic renal insufficiency 
(CRI) in 1994 and since then 2.529 patients have been 
registered.(1,2)  
When haemodialysis and transplantation progress were being 
developed, the first figures produced the frequency of terminal renal 
failure in children, provisionally estimated to be in the region of one 
or two cases per million inhabitants per year. (3) 
1.3. Prevalence  
1.3.1. Prevalence of HCV infection in haemodialysis in Sudan 
 In December 1994, the prevalence of HCV antibodies in 
haemodialysis patients in Khartoum Kidney Dialysis Center (KKDC) 
in Sudan was (34.9%) in the patients group and ( 5.41%) in staff 
members.(4, 5) 
1.3.2. Prevalence of HCV infection in Arab countries. 
 The prevalence of HCV in haemodialysis population in survey 
of 273 adult haemodialysis patient in 3 haemodialysis units in 
Jordan (Amman) was (1.7%) in healthy blood donors and (24.5%) in 
haemodialysis population, a percentage similar to what has been 
reported around the world and in the neighboring countries.(6) 
 Also it is found that the prevalence of anti-HCV antibodies 
among 5 different population groups including; healthy individuals, 
blood donors, hospital health care workers, renal dialysis patients 
and multiple blood transfusion in Libya,( 1.6%) among the general 
population, (1.2%  )among blood donors, (2%) among health care 
workers, (20.5%) among renal dialysis and( 10.8%) in the multiple 
blood transfusion group.(7) 
 In January 1991 and December 1993 the prevalence of 
positivity of anti-HCV antibodies in the haemodialysis patients was 
Sixty-four patients (24.4%) in Al-Jazerah hospital, Abu Dhabi, United 
Arab Emirates.(8) 
 In Hamad General Hospital, Doha, Qatar they screened 130 
patients on regular dialysis for anti-HCV antibodies by enzyme 
linked immunosorbant assay (ELISA) and confirmation by 
recombinant immunosorbent assay (RIBA). 58 (44.6%) were 
antibody positive.(9) 
 At prevalence of (2.7%) in the early 1990s, it is estimated that 
approximately 500,000 people in Saudi Arabia have been exposed 
to HCV.  Over ( 80% )of such individual remain infected and most of 
them progress to chronic hepatitis (CHC), cirrhosis and/or 
hepatocellular carcinoma (HCC). The recent reported prevalence of 
HCV infection in Saudi Arabia was approximately (1%).  This decline 
is largely due to the early implementation of testing of blood donors 
for HCV. 
 However, it is peritent that measures are taken to identify         
patients already infected and offer treatment to those with good 
prognostic factor.(10)                                                                            
         The age specific prevalence of antibody to HCV was studied.   
The prevalence of anti-HCV in apparently healthy Saudi (without 
overt liver disease) increased with the age, with a peak of 5% in 
those over 50 years of age.  The range which was (2.2 – 5%) is 
higher than that reported from any western countries.(11) 
 In another study, one hundred and forty nine patients with end-
stage renal disease on regular haemodialysis were screened for 
antibodies against HCV and HBs Ag.  The overall prevalence of anti-
HCV antibodies was (84.6%.( 12) 
 Twenty percent of pediatrics haemodialysis patients were 
found to be anti-HCV antibodies positive using first generation 
testing. It is possible that higher prevalence may be found using 
detection of viraemia by poly merase chain reaction (PCR) as the 
standard method of diagnosis. Screening of 20 Saudi children with 
renal failure showed a prevalence of (45%).) ( 13, 14) 
1.3.3. Prevalence of HCV infection in Europe and South 
America: 
        They screened a haemodialysis population in central Brazil by 
PCR method to assess the prevalence of HCV infection. An overall 
prevalence of( 46.7%) was found.(15) 
 In another study done by J A Oliva and et al in Creu Raja 
hospital, Barcelona, Spain.  They examined the prevalence of the 
IgG C virus 100-3 antibody (anti-HCV) in a group of 43 patients on 
haemodialysis, the anti- HCV prevalence was (30%).(16) 
 Anti-HCV antibodies  in haemodialyzed versus non-dialyzed 
patients was compared in kidney centre in Aga khan University 
Hospital in Karachi using enzyme immunoassay (EIA) (C 100-3-
AbboH) in 68 patients with chronic renal failure (CFR) who were on 
maintenance haemodialysis and 48 patients on conservative 
management.  In haemodialysis group 31 patients (46%) and in 
conservative group only 3 patients (6%) were anti-HCV positive.(17) 
1.4. Definitions and pathophysiology:- 
1.4.1. Definition:- 
 The Kidney Disease Outcomes Quality Initiative (K/DOQI) of 
the National Kidney Foundation (NKF) defines chronic kidney 
disease (CKD) as either kidney damage or a decreased kidney 
glomerular filtration rate (GFR) of <60 mL/min/1.73 m2 for 3 or more 
months. Whatever the underlying etiology, the destruction of renal 
mass with irreversible sclerosis and loss of nephrons leads to a 
progressive decline in GFR. The different stages of CKD form a 
continuum in time; prior to February 2002, no uniform classification 
of the stages of CKD existed. At that time, K/DOQI published a 
classification of the stages of CKD, as follows:  
• Stage 1: Kidney damage with normal or increased GFR (>90 
mL/min/1.73 m2)  
• Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2)  
• Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m2)  
• Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2)  
• Stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)  
 The K/DOQI definition and the classification of CKD allow 
better communication and intervention at the different stages.  
 The term chronic renal failure(CRF) is used to describe a 
patient who has residual renal function of less than 30%. 
 ESRD is term reserved for the stage of renal disease when 
replacement therapy, whether dialysis or transplantation is 
required.(1) 
1.4.2. Pathophysiology:- 
 According to Bicker’s hypothesis residual renal function 
derives from the remaining healthy nephrons in a kidney 
parenchyma in which all the diseased nephrons have ceased to 
function.  In support of this hypothesis, the classic experimental 
protocol of unilateral pyelonephritis provides two pieces of evidence, 
first is that the ratio of the majority of tubular function to glomerular 
filtration remains very similar in both healthy and the diseased sides 
that means, the glomerulotubular balance is preserved in 
experimental (CRF).  The next evidence is the demonstration of the 
homogeneous character of the population of residual nephrons in 
the diseased kidney.(2,18) 
1.5.  Etiology:- 
 The NAPRTCS registry confirms that different forms of 
obstructive uropathy (including reflux and dysplasia) account for 
almost 50% of the etiologies of renal failure.  Other relatively 
common causes of ESRD in children that are rare in adults include 
renal hypoplasia and dysplasia, hereditary nephritis, infantile 
polycystic disease, cystinosis and uremic medullary cystic disease.  
Focal glomerulosclerosis is the most common glomerulopathy 
leading to CRF in young children (accounting for 14.8% of all 
children with ESRD), but older children may suffer from many form 
of chronic glomerulonephritis.(1) 
 In conclusion, there are certain special features about the 
etiological distribution of CRF in children, such as the incidence of 
hereditary nephropathy, of renal hypoplasia and of vascular 
nephropathy and the absence of intestinal nephropathy of infectious 
origin without associated malformation of the urinary tract.(18) 
1.6. Signs of progressive loss of renal function:- 
 The databases have confirmed that children with chronic renal 
disease present in a different manner from similarly affected adults. 
The uremic syndrome is the hallmark of renal failure.  It includes 
such non-specific symptoms as lethargy drowsiness, itching, 
nausea, vomiting and paresthesias.  Although at times the 
pediatrician sees these late symptoms, for the child with renal 
insufficiency, earlier diagnosis and initiation of therapy, when subtler 
symptoms occur are advantageous.   
 The most common finding that should alert the pediatrician to 
the possibility of chronic renal disease is growth impairment.  The 
mean height of children entering the NAPRTCS CRI database is 1.4 
standard deviations below the mean.  For the NAPRTCS dialysis 
database, mean height at entry is 1.75 SD below the mean.  Short 
stature, particularly if associated with other symptoms, such as 
polyuria frequent bouts of dehydration, salt craving, bone 
deformities, abnormal tooth development, or anemia, should 
suggest that the affected patient might have chronic renal disease. A 
previous history of urinary tract infection or glomerulonephritis adds 
further support to this suspected diagnosis.(1, 18) 
1.7. Treatment:- 
 Numerous changes is recommended therapy have been made 
over the past few years and will continue to be made as more 
information becomes available about the metabolic abnormalities 
and the requirements for growth in these children. 
1.7.1. Non dialytic therapy for chronic renal insufficiency:-  
1.7.1.1. Diet:- 
Provide at least 100% of recommended daily allowance of caloric 
intake.  Protein intake is controversial; range 0.5 – 1.5 g/kg/d 
.Medium chain triglyceride should be added. 
1.7.1.2. Renal osteodystrophy:- 
    1, 25 dihydroxy cholecalciferol and calcium carbonate as a                   
calcium supplement and PO4 binder.    
1.7.1.3. Anaemia:- 
      May require iron or erythropoietin. 
1.7.1.4. Hypertension:- 
 Contro lsodium intake. If hyperreninemic, consider angiotensin 
– converting enzyme (ACEs) inhibitor. 
1.7.1.5. Acidosis:- 
   may improve with reduced protein &lipid intake, sodium citrate or 
NaHCO3, 2-4 mEq/kg/day. 
1.7.2. Dialytic therapy:- 
 In children, two techniques of maintenance dialysis are used, 
peritoneal and haemodialysis.  Several publications have been 
devoted to the pediatric problems of kidney transplantation.  Now, 
maintenance haemodialysis and transplantation are linked in the 
treatment of chronic uremia and cannot be considered separately.(19) 
1.7.2.1. Peritoneal dialysis:- 
 In the 1950s and 1960s, peritoneal dialysis was used to treat 
acute renal failure.  Treatment of CRF with peritoneal dialysis was 
not successful until reliable peritoneal access was developed in the 
late 1960s.  At that time several pediatric programs using 
intermittent peritoneal dialysis were developed.(1) 
1.7.2.2. Continuous Ambulatory peritoneal dialysis and 
continuous cycling peritoneal dialysis:- 
 In 1976, a new form of peritoneal dialysis that later became 
known as (CAPD) was described.  CAPD overcomes the relative 
inefficiency of the peritoneal membrane by exposing it continually to 
dialysate in the early 1980s; this form of dialysis was introduced as a 
form of therapy for children with CRF. In 1981 another form of 
peritoneal dialysis was introduced and was named Continuous 
Cycling Peritoneal Dialysis (CCPD).  Both of them can be done at 
home.  So permitting the patient to attend school and have relatively 
normal peer interactions.  Both forms of therapy are less costly than 
in-centre haemodialysis and either one can be used to treat even 
the smallest infant.(1) 
Complication:- 
 Hernias may occur, because of persistently increased intra 
abdominal pressure.  The most common complication of peritoneal 
dialysis is peritonitis, most often with coagulase-negative 
staphylococcus.(1) 
1.7.2.3. Haemodialysis:- 
The History of Haemodialysis: 
 The idea of removing solutes from body fluids by dialysis dates 
back to the beginning of the century.  Adel et al, 1983 at the Johns 
Hopkins Medical School in Baltimore, performed the first 
experimental haemodialysis in dogs.  George Haas from Geissen, 
Germany performed the first human dialysis.  He dialyzed four 
patients with terminal renal failure between 1924 and 1928 using 
large celloidin tube mounted in glass containers. 
 Willem Kolff at the Groningen University Hospital in the 
Netherlands introduced the first dialysis suitable for use in man in  
1943.  The first patient whose life was saved by treatment with the 
artificial kidney was a woman with acute renal failure.(20) 
Technical aspects of renal replacement therapy:- 
         The major components of a haemodialysis system include the 
blood circuit and the dialysate circuit, the central part of both circuits 
is the dialyser, where waste product, excess electrolyte and water 
are removed from the patient’s blood. Dialysis fluid and blood are 
pumped through the dialyser in a counter current direction, 
separated by the semi permeable membrane.(20) 
Composition of dialysate:- 
 The composition of dialysis fluid should be similar to that of 
normal interstitial body fluid, appropriately corrected for the   protein 
content of the latter. The basic principles, procedures and 
complications of haemodialysis are the same as in adult.(20) 
 The fact that kidney function can be replaced in part by 
maintenance haemodialysis, peritoneal dialysis or transplantation 
means that patient with end-stage renal failure can expect a much 
long survival than patients suffering from other sever disease such 
as cancer.  However, they have medical complication of the long-
term dialysis, which are:- 
1. Cardiovascular complications are worldwide a cause of mortality 
in patients on renal replacement therapy.  The European dialysis 
and transplantation association reports indicated that 52.6% of 
deaths in dialysis patients are due to cardiovascular 
complication. In Canada, 39.9% of deaths in patients with end-
stage renal failure were of cardiac origin and in New Zealand 
and Australia 46% of dialysis patient died from heart disease. 
2. Cerebrovascular accident:-  The incidence of cerebrovascular 
accidents in dialysis patient’s increase with age.  Patients aged 
15 to 34 years have prevalence of cerebrovascular accident 250 
times greater than that in general population.  Cerebrovascular 
accidents are slightly more common in adult with polycystic 
kidney disease (19.3%) due to the presence of vascular 
malformation. 
3. Infections diseases:-  Viral hepatitis plays only a minor role in the 
mortality of haemodialysis patients.  If Hbs Ag+ve positive 
patients are dialyzed in separate rooms with appropriate sanitary 
measures, the incidence of hepatitis B and its complication 
decrease.  The availability of hyper immune serum and hepatitis 
B vaccine, careful screening for infectious blood products and 
reducing the number of blood transfusion also decreases the 
incidence of hepatitis B and of hepatitis C in dialysis patient. 
Bacterial infections and septicemias are more common in 
patients with CRF than in normal population.(20) 
2. Hepatitis C Virus:-   
 Hepatitis C is a viral infection of the liver which in 1974 had 
been referred to as parenterally transmitted   hepatitis C until 
identification of the causative agent in 1989 by Choo et al.  The 
discovery and characterization of the HCV led to the understanding 
of its primary role in post-transfusion hepatitis and its tendency to 
induce persistent infection (21). HCV is a major cause of acute 
hepatitis and chronic liver disease, including cirrhosis and liver 
cancer. Globally, an estimated 170 million persons are chronically 
infected with HCV and 3 to 4 million persons are newly infected 
each year. No vaccine is currently available to prevent HCV infection 
and treatment of chronic hepatitis C is too costly for most persons in 
developing countries to afford.  Thus, from a global perspective 
view, the greatest impact on hepatitis C disease burden will likely be 
achieved by focusing efforts on reducing the risk of HCV 
transmission from nasocomial exposure (e.g. blood transfusions,  
unsafe injection practices) and high-risk behaviors (e.g. injection 
drug use). 
2.1. Prevalence:- 
 WHO estimates that about 170 million people, 3% of the 
world’s population, are infected with HCV and are at risk of 
developing liver cirrhosis and/or liver cancer. The prevalence of 
HCV infection in some countries in Africa, the Eastern 
Mediterranean, South-East Asia and the Western Pacific is high 
compared to some countries in North America and Europe.(10,21)  
 
 
2.2. Pathogen:- 
 Hepatitis C virus is one of the viruses (A, B, C, D, and E), 
which together account for the vast majority of cases of viral 
hepatitis.  It is an enveloped RNA virus in the flaviviridae family 
which appears to have a narrow host range.  Humans and 
chimpanzees are the only known species susceptible to infection, 
with both species developing similar disease. 
 An important feature of the virus is the relative mutability of its 
genome, which in turn is probably related to the high propensity 
(80%) of inducing chronic infection.  HCV is clustered into several 
distinct genotypes which may be important in determining the 
severity of the disease and the response to treatment (21) 
 
 
 
 
 
 
 
 
Table 1. 1.  Hepatitis C estimated prevalence and number 
infected by WHO region 
WHO Region Total 
population 
(millions) 
Hepatitis C 
prevalence 
rate % 
Infected 
populations 
(millions) 
No of 
countries 
by WHO 
region 
where 
data are 
not 
available 
Africa 602 5.30 31.9 12 
Americas 785 1.07 13.1 7 
Eastern 
Mediterranean 
466 4.60 21.3 7 
Europe 858 1.03 8.9 19 
South-East 
Asia 
1500 2.15 32.3 3 
Western 
Pacific 
1600 3.90 62.2 11 
Total 5811 3.10 169.7 57 
 
 
 
 
 Hepatitis C virus is one of the viruses (A, B, C, D, and E), 
which together account for the vast majority of cases of viral 
hepatitis.  It is an enveloped RNA virus in the flaviviridae family 
which appears to have a narrow host range.  Humans and 
chimpanzees are the only known species susceptible to infection, 
with both species developing similar disease. 
 An important feature of the virus is the relative mutability of its 
genome, which in turn is probably related to the high propensity 
(80%) of inducing chronic infection.  HCV is clustered into several 
distinct genotypes which may be important in determining the 
severity of the disease and the response to treatment.(21) 
2.3. Isolation of HCV:- 
        The HCV was cloned from the plasma of an experimentally 
infected chimpanzee with chronic NANBH. The genetic material 
(DNA & and RNA) was extracted and reverse transcribed in order to 
construct a complimentary library (8) .The resultant complementary 
DNA was inserted into a cloning vector (Phage gt 11). The vector 
containing the viral genome was then expressed in Escherichia Coli. 
         The protein expressed by the cloned DNA sequence was 
screened using an immunoblot assay against serum from a patient 
with chronic NANBH, presumed to contain antibodies to the 
responsible virus. After approximately 10-clones had been 
screened, an antigenic protein encoded by the HCV was isolated. 
Expression of the corresponding HCV complementary DNA in yeast 
allowed the development of an immunologic assay to detect 
antibody reactive against the protein.(22,23)  
2.4. HCV Genome:-  
         The entire HCV genome has been sequenced and all viral 
proteins encoded by the genome have been expressed. HCV 
appears to be a unique viral pathogen (novel type of virus) because 
little overall homology exists between the sequence of both the HCV 
genome and it’s encoded polypeptides and other known viral 
sequences.(24) 
            HCV is a small (30-60 nm), single stranded RNA virus with a 
lipid envelope and a genome length of approximately 10-kilo bases 
that code for approximately 3000 amino acids.(8,11) HCV is 
inactivated by heating (60° C for 30 min or 100° C for 2 min.) or UV 
exposure.(22,25) 
          The genome structure is similar to that of Flaviviruses Family 
(Human Flavi and Animal Pesti Viruses).(12) The Flaviviruses are 
mostly transmitted by arthropods such as mosquitoes and ticks.(24) 
           HCV structural proteins are encoded by contiguous 
sequences from the 5’ terminus, and non-structural (NS) proteins 
are encoded by sequences at the 3’ end.(27) 
              Hepatitis C virus nucleotide structure includes a single large 
open region frame that produces a polyprotein precursor. This in 
turn is cleaved into several polypeptides: a nucleocapsid core ©, 
various envelope structural regions (E1 & E2 / NS1) and several 
non-structural proteins (NS2, NS3, NS4, NS5), involved in viral 
replication, protein modification and assembly, thus the coding 
regions of the genome are flanked by non-coding regions at both 
ends (fig 1:1).(12) 
            The 5’ NCR is a highly conserved non-coding region, which 
has approximately 300 amino acid bases; located to the left of the 
nucleocapsid region and the 3’ non –coding sequence of about 50 
amino acid bases follows the NS coding region. 
             The 5’ NCR presumably exerts a regulatory influence upon 
replication and translation of the RNA genome. This region is the 
target of choice for PCR assays to detect HCV RNA.(13) 
             A feature of the E2 / NS1 region is a hyper variable domain 
of significant sequence heterogeneity.(26) There appears to be 
significant genetic diversity and several distinct subtypes have been 
distinguished with definite geographic distribution. This 
heterogeneity depend on the homology of the nucleotide sequences 
or there deduced amino acids sequences among different HCV 
isolates. HCV, which replicates, circulate as a heterogeneous 
mixture of closely related genomes containing a master (most 
frequently represented) sequence and a large spectrum of mutants, 
a genomic distribution referred to as Quasispecies.(26,28) Thus, HCV 
like many RNA virus, exhibit a high mutation rate and can therefore 
escape immune surveillance .This has implications for both vaccine 
development and responsiveness to anti-viral agents.(27) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.1.   Structure of HCV genome 
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2.4.1. Implications of HCV heterogenesis:- 
 Rigorous phylogenetic analysis of the NS 5 region has found 
clustering of nucleotide sequences into 6 major genotypes and a 
series of definable subtypes.(29)  The heterogeneity of certain 
regions , such as the E2 region, which has the highest mutation rate, 
may be the basis for the unreliability of antibody test, the 
phenomena of reinfection due to incomplete immunity and the 
difficulty in development of a useful vaccine(24).The high mutation 
rate in the E2/NS1 region allows the virus to elude host defense , 
C200 
which explains persistent and flare up of the disease .Thus at any 
one time , an individual may harbor several mutants , some of which 
are neutralized and others  are free ; the latter may be transmissible 
from mother to neonate , this state also explains the aggressive 
behavior of HCV noted in immune suppressed patients.(30) 
There is also a high mutation rate in infected individuals during 
anti-viral therapy.(31) These variations may explain the unpredictable, 
highly capricious response of patients, to treatment with interferon. 
There are also diagnostic implications where the subtypes of HCV 
possess different antigenic potential owing to the production of this 
similar protein. Thus the variability of HCV subtypes renders 
detection by PCR of questionable reliability if primers are chosen 
from a variable region of the genome (26).Perhaps the most 
significant clinical implication is the potential for repeated bouts of 
acute hepatitis with different subtypes and acute HCV super 
infection with a different subtype in a person with established HCV 
infection.(32) 
2.4.2. Genotypes of HCV:- 
               Currently there are 9 major genotypes and over 30 
subtypes. Genotype 1 is widely distributed through out the world.  
 In the United State and Western Europe, patients with chronic 
hepatitis and blood donors were found to be infected with subtypes 
1A, 1B .2B & 3A, while in Japan and Taiwan subtypes 1B, 2A & 2B 
are frequently found. In Thailand and Nepal, genotypes 1 & 3 are 
common where as genotype 4 are predominant in the Middle East, 
Egypt and Central Africa. Genotype 5 is found in South Africa, 6 in 
Hong Kong and Vietnam and recently new genotypes 7-9 have been 
identified in Vietnam. (33,34,35) 
2.5. Hepatitis C Virus infection:- 
2.5.1. Classification:- 
HCV infection was classified according to persistence of 
abnormal liver function for less or more than 6 months to:-  
 
 
2.5.1.1. Acute hepatitis:- 
  The acute response to HCV involves necrosis of the entire 
liver; most marked in the centrilobular areas and increased 
cellularity, which is predominant in the portal areas .The lobular 
architecture remains intact. Fatty change is rare, a diffuse 
mononuclear cellular inflammatory reaction causes expansion in the 
portal tracts, bile duct proliferation is common but bile duct damage 
is not often found.  Diffuse kupffer cell hyperplasia is present in the 
sinusoids along with infiltration of polymorphonuclear  leukocytes 
and esoinophils.(18)  
               The combination of bile duct damage and lymphoid 
aggregates should suggest infection with HCV; the single lesion 
thought to be most predictive of HCV infection is the presence of 
lymphoid aggregates.(36)  
2.1.5.2.  Chronic hepatitis:- 
             Individuals infected with HCV evidence a high percentage of 
chronic hepatitis on biopsy (35-63%), including lesions, suggesting 
the so called chronic persistent hepatitis , chronic active hepatitis, 
and chronic lobular hepatitis .The prevalence of cirrhosis or 
developing cirrhosis ranges from 20 to 58% (26,37) . 
            It is thought that the virus may promote cancer through 
cirrhosis although HCV mostly genotype 1B was found to be 
associated with hepatocellular carcinoma without the intermediate 
step of cirrhosis.(34)   In children long-term studies are needed to 
confirm this association . 
I-  Chronic persistent hepatitis (CPH):-   
 This is benign inflammatory process of the liver. The lobular   
architecture is always normal. Inflammation is limited to portal        
triads, and no significant fibrosis or cirrhosis found. Prognosis is 
good in childhood.(18) 
II- Chronic active hepatitis:-  
 It is characterized by resolving  inflammation, necrosis and 
fibrosis with the possibility of progression to cirrhosis and liver 
failure. 
 The above classification was renewed in 1994 to Knodell et al 
scoring system. This scores; portal inflammation, piece meal 
necrosis, lobular inflammation and fibrosis .Also it was name 
Histological Activity Index (HAI). 
2.5.2. Clinical features of acute infection:- 
 The clinical picture of HCV infection in children is 
indistinguishable from hepatitis A or B.(22)  
 The incubation period is 7-9 weeks (range 2-24weeks). Most 
pediatric patients are asymptomatic infections are usually mild (sub-
clinical) and insidious in onset . Fatigue is the most commonly 
reported symptom.(26)  Fever, malaise, nausea, often the presenting 
symptoms. Diarrhea often occurs and dark colored urine. Jaundice 
occurs in only 25% of patients.(38)  An enlarged tender liver usually 
occurs during the acute stage following transfusion of HCV infected 
blood; hepatitis C develops in approximately 80% of recipients.(39) 
 Typically, a fluctuating pattern of amino transferase (ALT) 
elevation occurs in about 80% of those in whom chronic HCV 
develops. These episodes of fluctuations in ALT presumably reflect 
waves of liver cell inflammation and cell death .The pattern of the 
ALT level may offer a prognostic indicator for progression to 
chronicity ; chronic hepatitis C occurs in 42% of patients with a 
transient ALT elevation, 87% of  patients with fluctuating ALT levels, 
and 95% of patients with persistent ALT elevation(26). Absence of 
HCV antibodies is seen in 10%of chronic hepatitis C, despite the 
presence of HCV RNA and evidence of liver disease.(26)  Although 
chronic elevations of aminotransferase levels are common , chronic 
HCV will progress to cirrhosis in only about half of the patients or 
about 25% of all those initially infected.(18)  
2.5.3. Natural Course of HCV infection:- 
The true natural history of HCV remains a major area of 
controversy in hepatology, reflecting the indolent by the logistical 
difficulties inherent in studying a disease that typically takes 
decades to evolve.(40) 
 Liver disease tends to evolve silently and insidiously, 
unheralded by physical signs or abnormal liver function test and thus 
progression is difficult to assess with standard serologic, 
biochemical and physical criteria. Follow up is best with periodic liver 
biopsies and quantitative estimate of viral load with PCR or 
branched DNA-based quantitative assays.(41) 
            It has been proposed that there are four patterns of HCV 
infections. The first is the pattern of recovery, which is seen in 15% 
of patients with viremia and acute hepatitis followed by resolution of 
viremia with persistence of antibody. 
            Next is the asymptomatic carriage and the stable chronic 
course in which patients have viraemia and acute hepatitis with 
subsequent decrease in ALT with intermittent ALT elevations and 
persistent viraemia over years. This is the predominant pattern seen 
in 70% of the patients. It is thought to be secondary to the 
emergence of quasispecies and relative in effectiveness of 
neutralizing antibodies. The third pattern is that of severe and rapid 
progression occurring in 20-30%of patients, which result in 
persistent elevation of hepatic enzymes, persistent viraemia and a 
more rapid progression to cirrhosis. The last pattern is that of acute 
resolving hepatitis with persistent viral replication (asymptomatic 
carriage) .This occurs in 5-10 % of patients.(40,42) HCV generally 
develops chronic hepatitis in about5- 10 years, cirrhosis in about 10-
20 and HCC in about 20-30 years.(40) 
 The natural history of hepatitis C in sporadic and low risk 
cases is that of a relatively benign and very slowly developing 
process. (41)  The few published studies of chronic hepatitis C in 
children, are based on patients in the high risk category who 
manifest a disease spectrum that broadly resembles that course of 
hepatitis C in adults. 
Figure 1.2: Natural course of hepatitis C  
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Little is known about the natural history of parentally acquired HCV 
infection. In a recent study by Palomba et al,(40) seven HCV positive 
children were followed up for a period of 65 months (range 26-90 
months).   Viraemia was evident in these children at the most recent 
follow up visit. Liver biopsies of five children showed chronic 
persistent hepatitis. These preliminary result suggest that perinataly 
acquired HCV may persist indefinitely, causing chronic indolent 
hepatitis.(40) 
 It was found that there were 5 situations associated with an 
accelerated course of infection .These included concurrent alcohol 
use , hepatitis B infection ,iron overload, aflatoxin exposure and 
immunosuppressive state such as HCV infection and chronic renal 
dialysis.(41) 
2.5.4.  Chronic infection and consequences:- 
 About 80% of newly infected patients progress to develop 
chronic infection.  Cirrhosis develops in about 10% to 20% of 
persons with chronic infection, and liver cancer develops in 1% to 
5% of persons with chronic infection over a period of 20 to 30 years.  
Most patients suffering from liver cancer who do not have hepatitis B 
virus infection have evidence of HCV infection.  The mechanisms by 
which HCV infection leads to liver cancer are still unclear.  Hepatitis 
C also exacerbates the severity of underlying liver disease when it 
coexists with other hepatic conditions.  In particular, liver disease 
progresses more rapidly among persons with alcoholic liver disease 
and HCV infection.(10) 
2.5.5. Means of transmission:- 
 HCV spread primarily by direct contact with human blood.  
Transmission through blood transfusion that are not screened for 
HCV infection, through the reuse of inadequately sterilized needles, 
syringes or other medical equipment, or through needle-sharing 
among drug-users, is well documented.  Sexual and perinatal 
transmission may also occur, although less frequently.  Other modes 
of transmission such as social, cultural, and behavioral practices 
using percutaneous procedures (e.g. ear and body piercing, 
circumcision, tattooing) can occur if inadequately sterilized 
equipment is used.  HCV is not spread by sneezing, hugging, 
coughing, food or water, sharing eating utensils, or casual contact. 
 In both developed and developing countries, high risk groups 
include injecting drug users, recipients of unscreened blood, 
hemophiliacs, dialysis patients and persons with multiple sex 
partners who engage in unprotected sex. 
 In developed countries, it is estimated that 90% of persons 
with chronic HCV infection are current and former injecting drug 
users and those with a history of transfusion of unscreened blood or 
blood products. 
 In many developing countries, where unscreened blood and 
blood products are still being used, the major means of transmission 
are unsterilized injection equipment and unscreened blood 
transfusions.  In addition, people who use traditional scarification 
and circumcision practices are at risk if they use or re-use 
unsterilized  tools.(10,18) 
2.5.6.  Diagnosis:- 
 Diagnostic tests for HCV are used to prevent infection through 
screening of donor blood and plasma, to establish the clinical 
diagnosis and to make better decisions regarding management of a 
patient.  Diagnostic tests commercially available today are based on 
EIA for the detection of HCV specific antibodies.  EIAs can detect 
more than 95% of chronically infected patients but can detect only 
50% to 70% of acute infections.(45,46) 
 A recombinant immunoblot assay (RIBA) that identifies 
antibodies which react with individual HCV antigens is often used as 
a supplemental test for confirmation of a positive EIA result. 
 Testing for HCV circulating by amplification tests RNA (e.g.:  
PCR or branched DNA assay) is also being utilized for confirmation 
of serological results as well as for assessing the effectiveness of 
antiviral therapy.  A positive result indicates the presence of active 
infection and a potential for spread of the infection and/or the 
development of chronic liver disease.(46) 
2.5.6.1. Virology:- 
 The preferred sample for virological investigation is plasma 
from a tube anti-coagulated with ethylenediamine tetra-acetic acid 
(EDTA).  The plasma is suitable for both antibody and HCV-RNA 
testing.  If plasma is unavailable, then serum should be separated at 
low speed centrifugation and stored at -20oC or lower.(10) 
1. Detection of HCV antibodies by the enzyme immunoassays 
 The enzyme immunoassay (EIA) is the methodology of choice 
to detect antibodies against HCV specific antigens in individuals 
exposed to HCV.  The EIA assays should have adequate sensitivity, 
appropriate specifity.  A negative EIA test is sufficient to exclude a 
diagnosis of chronic HCV infection in immuno-competent patients.  
The initial EIA-reactive (IR) results have to be confirmed.  Firstly, the 
test should be repeated so that the serological reaction is shown 
repeat ably reactive (RR).  This sample is then considered to be 
“EIA-positive”.  The patient should be re-bled and re-tested using the 
same reagents to confirm that the first EIA-positive sample did 
indeed come from the patient.  Then, the RR EIA-positive sample 
should be referred to a reference laboratory for confirmation of 
infection by PCR.  If HCV-RNA is detected. CHC is confirmed.  In 
those cases where HCV-RNA is not detected, the patient could have 
either, resolved past HCV infection, or a false-positive HCV EIA test 
result.(10,45,46) 
The EIA assays are considered to have very high specificity of over 
99%. Studies of EIA-positive samples in KSA have shown that, they 
are very likely to be reactive by RIBA, and the positive predictive 
value of EIA assays reaches 97%.  The EIA may be falsely negative 
in immuno-compromised patients (for example HIV, renal failure and 
post transplant) and in the stages of an acute infection.  Therefore, 
the HCV-RNA detection should be carried out in suspected 
cases.(45,46) 
2. HCV-RNA detection:- 
 Viral RNA detection tests for HCV can be either qualitative or 
quantitative.  It is recommended that the blood sample should be 
taken into tubes with the anticoagulant (EDTA), which provides more 
stable RNA. 
 The HCV-RNA qualitative test is usually the more sensitive 
and can detect less than 50 IU/ml (<100 copies/ml) using target 
amplification assays such as reverse transcriptase-polymerase 
chain reaction (RT-PCR).  Transcription mediated amplification 
(TMA), a newly developed technique has been shown to be more 
sensitive with a limit detection of less than 5 IU/ml.  Because of this 
relative sensitivity, a qualitative assay will confirm viraemia and 
assess the  SVR.  Quantitative tests should be used to determine 
the pre-treatment viral load and to assess the early response to 
therapy at 12 weeks.(46) 
2.5.7. Treatment:- 
 Antiviral drugs such as interferon taken alone or in 
combination with ribavirin, can be used for the treatment of persons 
with chronic hepatitis C, but the cost of treatment is very high.  
Treatment with interferon alone is effective in about 10% to 20% of 
patients.  Interferon combined with ribavirin is effective in about 30% 
to 50% of patients.  Ribavirin does not appear to be effective when 
used alone.(47,48,49) 
2.5.8. Prevention:- 
 There is no vaccine against HCV. Research is in progress but 
the high mutability of the HCV genome complicates vaccine 
development. Lack of knowledge of any protective immune 
response following HCV infection also impedes vaccine research.  It 
is not known whether the immune system is able to eliminate the 
virus.  Some studies, however, have shown the presence of virus-
neutralizing antibodies in patients with HCV infection. 
In the absence of a vaccine, all precautions to prevent infection must 
be taken including:- 
♦ Screening and testing of blood and organ donors. 
♦ Virus inactivation of plasma derived products. 
♦ Implementation and maintenance of infection control practices 
in health care settings, including appropriate sterilization of 
medical and dental equipment. 
♦ Promotion of behaviour change among the general public and 
health care workers to reduce over use of injections and to use 
safe injection practices .  
♦ Risk reduction counseling for persons with high-risk drug and 
sexual practices.(10) 
3. Hepatitis B Surface Antigens (Hbs Ag):- 
 It is common practice to look for HBsAg during the first 
assessment so that chronic carriers can be further investigated and 
special precautions can be taken in handling their blood samples (49). 
 It is a common infection worldwide although the prevalence 
varies considerably from country to country.  The incubation period 
is between 6 weeks to 6 months, and it is common for CRF patients 
to have a relatively asymptomatic course while affected dialysis staff 
frequently have extreme fatigue, jaundice, arthritis and anorexia.  
Between 10% and 14% of non-uraemic patients who develop 
hepatitis B will progress to chronic active or chronic persistent 
hepatitis, and between 1% and 3% will develop fulminant hepatitis, 
which carries a high mortality rate.(20)   
 The eighteenth combined report (Brunner 1987) on regular 
dialysis and transplantation in Europe patients and staff of 
hemodialysis units varied widely between countries, surprisingly, the 
majority of centers in Austria, Belgium and France were reported not 
to use separate rooms for haemodialysis of patients positive for the 
HbsAg. The reports indicated that the higher the number of HbsAg 
positive patients on treatment, the higher the number of new cases; 
however, the number of new cases of hepatitis B in staff appeared 
to be only weakly related to the number of HBs Ag positive patient 
on HD.few member staff were infected in most European countries 
but in some Eastern European countries, where there was a high 
proportion of HBsAg positive patients on  haemodialysis centre, 
there were also high number of infected staff. 
 A dramatic decrease in the number of staff contracting 
hepatitis has been observed in countries where active immunization 
against hepatitis B has been introduced(20). 
 
4.Hepatitis B&C screening:- 
 If the initial blood test for HbsAg was negative it should be 
repeated to confirm that the patient remain free of hepatitis B before 
decisions are made about the form of replacement therapy.  If the 
initial test was positive it should be repeated and tests for HBeAg 
and anti-HBeAg performed.  HBsAg positive have the same survival 
on regular dialysis as HBsAg negative patients but a poorer 
prognosis and higher incidence of hepatic disease after renal 
transplantation.  Patients who are HBsAg positive, particularly if they 
are also HBeAg positive, are better managed by chronic ambulatory 
peritoneal dialysis or home dialysis, which reduces the risk of 
transmission to the staff and fellow patients, though this has become 
a less important considerations since the introduction of vaccine.  
Patients who are negative for HBsAg are offered vaccination if they 
do not have naturally acquired immunity; a test for anti- HBsAg is 
therefore performed.  In many centers, those who have no 
detectable surface antibody are offered vaccination with serum 
derived or yeast derived  vaccines before they undergo dialysis, or 
immediately after starting.  It is essential to confirm that protective 
antibody levels have been achieved; prolonged courses of four or 
more injections, and high doses, are required in some uraemic 
patients, particularly those who have received immunosuppressive 
therapy.(49)   
 The recent development of an antibody test for hepatitis C has 
shown that previous exposure to this virus (probably by routes 
similar to those for hepatitis B) is not uncommon among patients on 
dialysis, an incidence of 5.5 percent in Germany.  So far there are 
no available tests for infectivity comparable to those for HBsAg and 
HBeAg.  When such a test becomes available it will become a 
routine part of predialysis assessment, since epidemics of  hepatitis 
C occur in dialysis units.  For the moment we have only the 
unsatisfactory option of treating all antibody positive patients as 
infectious, while this a reasonable policy for blood donors ,  since 
the incidence of permanent carriage of the virus is high in parenteral  
hepatitis C, it raises more ethical problem in the case of dialysis 
patients who may have their mode of treatment changed because 
the probability, not the certainty,  that they are infectious.(49) 
 There are particular problem in areas of low prevalence, at a 
time when there is no confirmatory test for doubtful positives.  
Consequently one cannot be dogmatic but in our view screening for 
hepatitis C antibody should now become a routine part of predialysis 
assessment, but they should be used with  discretion.(49) 
5. HCV/HIV Co-infection:-   
The prevalence of HCV infection in patients with HIV diseases 
has been reported to vary from 26% - 97 % (50). HIV co-infection 
result in an increased hepatitis C viral load and accelerate liver 
disease progression associated with CD4 decline due to HIV 
disease. The accelerated liver disease result in 16-fold increase in 
end stage liver disease, 5.6 fold increase in hepatocellular 
carcinoma and a 7-fold increase in mortality.(51) New data suggest 
more rapid development of AIDS in hepatitis C co-infected patient 
who developed liver disease.(51) 
      The mechanism of this may be due to change in the immune 
system. The expansion of T helper cell (Th) type 1 clone and Th 
recognition of multiple epitopes are important in the elimination of 
HCV. Co-infected lymphocytes produce a Th II response rather than 
the desire Th I, which impaired the host immune  response to 
HCV.(40)              
6. Hepatitis and CRF:- 
 Despite major improvements in renal replacement therapy the 
immune function of uraemic patients remains poor.  In part, these 
immune aberrations are linked to the uraemic status and are present 
before the onset of any renal replacement therapy.(52) 
 However, treatment such as hemodialysis with cuprophan 
membranes may contribute to reduce immune capacity.  From a 
practical point of view, these data strongly favour the use of more 
biocompatible membranes, which have fewer complement activating 
properties, and non-pyrogenic, endotoxin-free, and eventually 
acetate-free, dialysates for renal replacement therapy.  Moreover, 
recent knowledge of fundamental immunology, once fully applied to 
the study of the immune deficit of chronic uraemia, may lead to the 
definition of effective immuno-modulating strategies.(52) 
 Acute and chronic hepatitis can pose a difficult diagnosis in 
CRF patients .The clinical picture of viral hepatitis is 
indistinguishable form that of drug induced hepatitis, toxic hepatitis 
or alcoholic hepatitis.  Identification of the causative virus is 
essential because it has implication on treatment and prognosis.  
Due to the immunosuppressive effect of ureamia, viral hepatitis in 
these patients is often mild compared to the infections in non-
uraemic subjects, who mount more vigorous inflammatory 
responses. 
 As cell mediated immunity  which is important for terminating 
hepatitis B infection  is impaired  there is increased tendency for the 
uraemic patient to develop chronic liver disease as a result of viral 
hepatitis(52). Following acute viral hepatitis caused by the B or 
non-A, non-B, chronic liver disease may develop in the form of 
chronic active hepatitis.  The latter is a serious complication which 
eventually progresses to cirrhosis.(52) 
7. Hepatitis and Haemodialysis:-  
 Patients treated with haemodialysis usually show abnormal 
stored liver function test.  Approximately 30% of haemodialysis 
patient present mild elevation of transaminase.  Hepatitis B and C 
are the main cause of liver disease in such patients. 
 With the extensive use of haemodialysis in the 1960s it 
became apparent that viral hepatitis was major problem associated 
with this therapy.  In 1972 it was found that patient submitted to 
chronic hemodialysis were at great risk of acquiring HBV infection.  
Subsequently, several studies confirmed the incidence of HBV 
infection in hemodialysis unit; at least one serological HBV marker 
was positive in about 40%; the prevalence of serological HBV 
markers in patient dialyzed at home is lower (5%-6%)  suggesting 
that transmission of HBV  from other patient or hospital personnel 
important in the spread of HBV infection in hemodialysis unit(52). 
8. Hepatitis in renal dialysis unit:- 
 Out breaks of hepatitis affecting both patients and staff began 
to occur soon after intermittent hemodialysis units were established 
for the treatment of patient with CRF. In the beginning it was 
assumed that these outbreaks were due to hepatitis B and 
transfusion of the patient was restricted and washed frozen cell 
substituted for whole blood in an effort to prevent the virus entering 
the units.  Stringent precautions against cross-infection were also 
introduced (PHLS 1968) but did not terminate out breaks already in 
progress or prevent new ones from starting.(53)  Infection control 
policy now is adopted. 
 
 
 
 
 
 
 
 
 
 
JUSTIFICATION 
1. Although many studies regarding the prevalence of HCV were 
conducted in Sudan, the prevalence of HCV in children with 
CRF is not known.  
2. CRF patients are at risk of developing HCV infection  i.e. those 
needing blood transfusions an appreciable number of hospital 
inpatients and outpatients and are a great burden to the health 
system, family and society. 
3. With the increased facilities of haemodialysis, patients with 
ESRD are living longer. Consequently, the chance of acquiring 
infection is increased in these immunocompromised patients. 
4. HCV has become the most common cause of chronic liver 
disease with no effective vaccine and non-sustained response 
to treatment  
5. Higher risk of mortality in patients referred for renal 
transplantation who were anti-HCV positive compared to anti-
HCV negative 
6. Yet in Sudan there is no protocol to screen blood bank and 
donor for HCV. 
 
 
 
  OBJECTIVES      
1. To determine the prevalence of HCV infection in children with 
chronic renal failure in Khartoum state.  
2. To study the risk factors for transmission of HCV among 
children with CRF. 
3. To correlate the presence of HCV antibodies to liver disease 
activity.   
  
  
 
 
 
 
 
 
 
 
 
 
 
2. MATERIALS AND METHODS 
         
 2.1. Study design:- 
 This is a descriptive comparative hospital based study.  
2.2. Study area:- 
 This study was conducted at the following six dialysis centers 
and hospitals:- 
         D1 = Dr. Salma dialysis and kidney transplantation centre. 
         D2 = Dialysis unit in Khartoum teaching hospital. 
         D3 = Suba University hospital  
         D4  = Renal Center in Khartoum North hospital. 
         D5 = Ahmed Gasim Paediatric Hospital 
         D6 = Dialysis unit in military hospital – Omdurman. 
2.3. Study duration:- 
             This study was conducted during the period from the 1st of 
Dec 2004 – end of June 2005.  
2.4. Study population:- 
The study populations were children aged 0 – 18 years.     
2.4.1. Patients:-        
         The study was conducted in children aged 0-18 years who 
presented to the above mentioned hospitals with chronic renal 
failure or end-stage renal disease and maintained on either 
conservative therapy or dialysis. 
 The study was conducted in three groups: - 
1. Children on conservative management.   
2. Children on peritoneal dialysis.  
3. Children on haemodialysis.  
2.4.2. Control group:- 
          Healthy children aged 0-18 years matched for age and sex 
were enrolled in the study; they were randomly selected from Basic 
Schools, neibourghers, Relatives& Co-patients. 
2.4.3. Case definitions:- 
           Chronic renal failure is defined as an irreversible reduction in 
the GFR to less than 25% of normal level, for at least three months. 
It is staged according to residual renal function into: 
• Stage 1:Kideny damage withnormal or increased GFR > 90ml/ 
min 1.73m 
• Mild reduction in GFR:89 – 60ml min 1.73 m. 
• Moderate reduction in the GFR: 59-30ml min 1.73 
• Sever reduction in the GFR :29-15ml min 1.73m 
• Renal Failure:15ml min 1.73m 
2.4.4. Inclusion criteria:- 
     All children aged 18 years or below with a diagnosis of CRF or 
ESRD, after taking informed verbal or written consent from parents 
or caregiver. 
 
2.4.5. Exclusion criteria:- 
    -Refusal to participate in the study. 
    -transplanted patient  
2.4.6. Sample size:- 
- Total coverage 50 patients.  
- 50 cases control group. 
2.5. Study techniques and tools:- 
2.5.1. Questionnaires:- 
 Detailed questionnaire was completed for all the study 
subjects. This provided an account for:    
     - Data regarding  medical record, type of center, Socio-
demographic data, serology at the start of dialysis (Hepatitis B, C 
and HIV), number of HD sessions per week, time interval from 
diagnosis of ( ESRD) to initiation of( HD) in months, number of blood 
transfusions, number of (HD) centers utilized, number of surgical 
procedures, hospital admissions, parenteral injection and traditional 
treatment and practices.  
    Clinical examination was conducted. Symptoms and signs were 
recorded with concentration on Pallor, jaundice and signs of chronic 
renal and liver diseases, anthropometric measurements such as 
weight and height using tape measurement were recorded.    
           The researcher collected the data personally by interviewing 
patients, parents or caretaker while the patients receiving 
haemodialysis treatment  or came for follow up in the referred clinic. 
Additional information was obtained from the medical staff. 
2.5.2. Blood Sampling:- 
 Sterile disposable syringes labeled for each case was used to 
collect 5cc venous blood. The blood was allowed to clot in a test 
tube (vaccu container), then transferred to the laboratory where it 
was centrifuged and the serum separated in plain container. The 
serum was stored in –20 degrees C until further analysis.  
    Third Generation Enzyme Immuno- assay was used for analysis 
of the samples and the positive cases were retested with ELISA 
from different company.  
2.5..3. Research team:- 
• The author. 
• The lab technicians. 
• The computer technician.  
2.5.3.1.  The input of the author:- 
• Selection of the cases. 
• Filling the questionnaire. 
• Physical examination of the patients. 
• Collection of the samples& centrifugation. 
• Analysis of the data. 
Principle of the test:- 
DIA. PRO were used in this study from diagnostic Bio probes 
Sol via columella ^ 31  20128  Milano – Italy. 
This is based on highly sensitive technique, which detects 
antibodies against (HCV) in human serum and plasma. Thus 
immunodiagnosis of (HCV) infection is based on detection of host 
generated antibodies to viral proteins. This technique utilizes a 
combination of recombinant proteins with the sequence of both 
(HCV) structural and nonstructural proteins i.e. core, NS3, NS4, 
NS5. It has improved sensitivity over the previous generations. 
The recombinant antigens are coded onto the microwells, diluted 
samples and controls are then incubated. Antibodies to HCV, if 
present, bind to the immobilized (HCV) antigens in the microwell 
during the incubation period. The microcells are then thoroughly 
washed with a wash buffer to remove excess of unbound anti (HBV 
)or other human IgGs, which may interfere with the test. Enzyme 
conjugate, antihuman IgG conjugated with horse Raddish 
Peroxidase (HRPO) is added. The excess conjugate is again 
washed. At this stage the microcells hold only the bound antigen-
anti (HCV) enzyme conjugate complex. In the next step, freshly 
prepared substrate solution incubated with complex in the 
microcells. The enzyme substrate reaction leed to development of 
yellow colour, which is indicative of the antigen- antibody reaction, 
which had occurred in the microcell. The last step is to add the stop 
solution and the optical density of the developed colour is read 
photometrically.  
 The samples  also screened for( HBs) antigen and (HIV) by 
ELISA, and tested for liver enzyme (ALT). 
2.7.  Ethical consideration:- 
Written consents were taken from: 
• Directors of the different hospitals. 
• Doctors on charge of CRF patients. 
• Parents of the children. 
• After diagnosis of HCV infection, information was given to 
each caring unit for further management. 
2.8.  Data entry & statistical methods:- 
   All data collected from each child were coded for subsequent 
computer processing and analysis. Frequencies and descriptive 
statistics were obtained for all variables. Chi-Square test was 
computed for selected variables. The level of significance was taken 
as p< 0.05 using T test for the risk factors. 
2.9. Difficulties encountered:-  
- Kits were expensive. 
- Blood sample transportation. 
- Convincing the parent and their children to take blood 
samples. 
 
 
 
 
 
  
 
 
 
 
 
 
 
3.  RESULTS 
3.1. Socio– Demographic Characteristics of children in the      
        study:- 
3.1.1.Age distribution of the study group:-  
 Distribution of the study group according to their age. The age 
group between 0-18 yrs divided in to four groups. The majority, 31 
patients (62.0%) were between 12 – <18 yrs, aged 6 - <12 years 
were 13 patients (26.0%), 3(6%) were 18 yrs old and 2 patients 
(4.0%) were less than six year. The same for the control group as 
shown in Fig (3.1.1).  
3.1.2. Sex distribution of the study group:- 
 Distribution of the study group according to their gender. The 
majority of children, 33 (66.0%) were male and 17 (34.0%) were 
female in the patients group and the same distribution for the control 
group, the male: femle ratio 1.8:1 as shown in Fig (3.1.2). 
3.1.3. Educational level of the study group:- 
 The majority of cases in CRF group; 37 (74.0%) were primary 
school level, 10 (20.0%) were secondary school level and 3 (6.0%) 
were illiterate. Also in the control group, the majority 29 (58.0%) 
were primary school level, 16 (32.0%) were secondary school level , 
only three (6.0%) were illiterate , 1(2%)was from Quran school and 
one was university graduate  (P 0.360) as shown in Fig (3.1.3). 
3.1.4. Residence of the study group:- 
 Distribution of the study group according to their residence. 
Most of the patients, 23 (46.0%) were from urban area, 18 (36.0%) 
were   from rural and 9 (18.0%) were from suburban area. While the 
majority of the control group 23 (46.0%) were from suburban area, 
21 (42.0%) were from urban   and 6 (12.0%) were from rural (P 
0.002) as shown in Fig (3.1.4). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.1.1.  Age distribution of the study group 
                                               (n = 100) 
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Figure 3.1.2.  Gender distribution of the study group 
                                                 (n = 100) 
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Figure 3.1.3. Educational level of the study group 
(n = 100) 
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Figure 3.1.4. Residence of the study group 
(n = 100) 
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3.1.5. Fathers’ educational level:- 
 The educational level of the fathers in the study group. The 
majority 16 (32.0%) were primary school level, 12 (24.0%) were 
secondary level, 9 (18.6%) were illiterate, 8 (16.0%) were post 
secondary school and 5(10.0%) were Quran school. While in the 
control group the majority 16 (32.0%) were secondary school level, 
12 (24.0%) were primary school level, 11 (22.0%)  were post 
secondary level, 9 (18.0%) were illiterate and 2 (4.0%) were Quran 
school educated  (p   0.566) as shown in table(3.1.5). 
3.1.6. Mothers’ educational level:- 
 The educational level of the mothers in the study group. The 
majority  of the mothers of patients with (CRF) , 18 (36.0%) were 
illiterate, 16 (32.0%) were primary school level, 11 (22.0%) were 
secondary  school level ,3 (6.0%) were post secondary school  and 
2 (4.0%) were Quran school. In contrast , in the control group the 
majority 19 (38.0%) were secondary school level, 13 (26.0%) were 
primary  school level, 10 (20.0%) were illiterate ,7 (14.0%) were post 
secondary   school level and 1 (2.0%) was Quran school graduated  
( P 0.052) as shown in table(3.1.6). 
 3.1.7. Fathers’ occupation:- 
 Occupation of the fathers in the study group. In the patients 
group, the majority 16 (32.0%) were civil servants, 15 (30.0%) were 
unskilled labourers, 8 (16.0%) were skilled labourers, 7 (14.0%) 
were farmer’s shepherds and 4 (8.0%) were jobless. In the control 
group, the majority 27 (54.0%) were civil servants, 7 (14.0%) were 
professional, 6 (12.0%) were unskilled labourers, 3 (6.0%) were skill 
labourers, 3(6.0%) were unemployed and 2 (4.0%) died   (P  0.00) 
as shown in table (3.1.7). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 3.1.5. Fathers’ educational level (n 
(n = 100) 
Father’s  
education 
Case 
n 
(%) 
Control 
n 
(%) 
Total 
n 
(%) 
Illiterate  09 
(18.0%) 
09 
(18.0%) 
18 
(36.0%) 
Primary  16 
(32.0%) 
12 
(24.0%) 
28 
(56.0%) 
Secondary  12 
(24.0%) 
16 
(32.0%) 
28 
(56.0%) 
Post secondary 08 
(16.0%) 
11 
(22.0%) 
19 
(38.0%) 
Quran school  05 
(10.0%) 
02 
(4.0%) 
07 
(14.0%) 
Total 50 
(100.0%) 
50 
(100.0%) 
 
 
(P 0.566) 
 
 
 
 
 
  
 
 
 
 
 
Table 3.1.6: Mothers’ educational level 
(n = 100) 
Mother’s education Case 
n 
(%) 
Control 
n 
(%) 
Total 
n 
(%) 
Illiterate  18  
(36%) 
10 
 (20.0%) 
28 
 (56.0%) 
Primary  16 
 (32%) 
13  
(26.0%) 
29 
 (58.0%) 
Secondary  11 
 (22%) 
19 
 (38.0%) 
30 
 (60.0%) 
Post secondary 03  
(6.0%) 
07  
(14.0%) 
10 
 (20.0%) 
Quran school  02 
 (4.0%) 
01 
 (2.0%) 
03 
 (6.0%) 
Total 50 
 (100.0%) 
50  
(100.0%) 
 
 
(P. 0.052) 
 
 
 
 
 
 Table 3.1.7: Fathers' occupation 
(n = 100) 
   Father’s occupation Case 
n 
(%) 
Control 
n 
(%) 
Total 
n 
(%) 
Professional  - 07 
(14%) 
07 
(14.0%) 
Civil servant, Employee’s 
and merchant 
16 
(32.0%) 
27 
(54.0%) 
43 
(86.0%) 
Skill labourers  08 
(16.0%) 
03 
(6.0%) 
11 
(22.0%) 
Un skill labourers 15 
(30.0%) 
06 
(12.0%) 
21 
(42.0%) 
Farmers and shepherd 07 
(14.0%) 
02 
(4.0%) 
09 
(18.0%) 
Workers  04 
8.0%) 
03 
6.0%) 
07 
(14.0%) 
Died 0 
(0.0%) 
02 
(4.0%) 
02 
(4.0%) 
Total 50 
(100.0%) 
50 
(100.0%) 
 
(P 0.00) 
 
 
 
 
 
Social background of the study group:- 
 The type of housing, toilet and availability of electricity in the 
study group as shown in table (3.1.8). 
Housing:-  
 The majority of houses, 28 (56.0%) in the patients group while 
30 (60.0%) in the control were made from bricks,  17 (34.0%) 
compare to 14 (28.0%) were from mud, four (8.0%) compare to 
1(2.0%) were from straw and 1 (2.0%) compare to 5 (10.0%) were 
from concrete (P   0.158). 
Toilet:- 
 The majority of patients; 40 (80.0%) had pit latrine (private) vs 
29 (58.0%) in the control group, 7 (14.0%) compare to 13 (26.0%) 
had siphon, 2 (4.0%) compare to 4 (8.0%) had common latrines and 
1 (2.0%) compare to 4 (8.0%) were open space (P  0.490). 
Electricity:- 
 The majority 37(74.0%) had electricity both in the patients and 
control group, while 13 (26.0%) of both groups had no electricity ( P 
0.490). 
Water Supply:- 
 Around two third of the patients 33 (66.0%) had piped in, 8 
(16.0%) had traditional well, 6 (12.0%) had deep well, 3 (6.0%) were 
supplied from the Nile and no one had piped out. While, in the 
control group, 29 (58.0%) had piped in, 12 (24.0%) were supplied 
from the Nile, 5 (10.0%) had traditional well, 3 (6.0%) had piped out 
and 1 (2.0%) had deep well. (P  0.012) as shown in Fig (3.1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1.8 Social background of the study group; housing, toilet  and 
electricity 
 Case 
n 
Control 
n 
Total             p.val 
n 
(%) (%) (%) 
Housing 
Straw 04 
(8.0%) 
01 
(2.0%) 
05 
Mud 17 
(34.0%) 
14 
(28.0%) 
31 
Bricks 28 
(56.0%) 
30 
(60.0%) 
58 
Concrete  01 
(2.0%) 
05 
(10.0%) 
06 
Total 50 
(100.0%) 
50 
(100.0%) 
P. 0.158 
Toilet 
Common latrine  02 
(4.0%) 
04 
(8.0%) 
06 
Pit latrine (private) 40 
(80.0%) 
29 
(58.0%) 
69 
Pit latrine   02 
(4.0%) 
02 
Siphon  07 
(14.0%) 
13 
(26.0%) 
20 
Open space  01 
(2.0%) 
02 
(4.0%) 
03 
Total 50 
(100.0%) 
50 
(100.0%) 
P. 0.490 
Electricity 
Yes  37 
(74.0%) 
37 
(74.0%) 
74 
No 13 
(26.0%) 
13 
(26.0%) 
26 
Total 50 
(100.0%) 
50 
(100.0%) 
P. 0.490 
 
 
 
 
 
 
  
 
Figure 3.1.8: Water supply of the study group 
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3.2.  Clinical pattern of the study group:- 
3.2.1.  Presenting complain of the study group:- 
 The clinical symptoms among the study group were studies 
31 patients (62.0%) while 5   (10.0%) in the control group 
complained of malaise (P 0.00). 25 (50.0%) compare to 1 (2.0%) 
had vomiting, 25 (50.0%) compare to 0 (0.0%) had nausea (P 0.00) 
for both symptoms and 24 (48.0%) compare to 2 (4.0%) had 
anorexia (P  0.00). Fever was evident in 19 patients (38.0%) 
compare to 10 (20.0%)  (P 0.038). 18 (36.0%)  compared to 4 
(8.0%) suffered from abdominal pain  (P  0.001). 12 (24.0%)  
compared to 0 (0.0%) had constipation ( P 0.00). 9 (18.0%) 
compared to 2 (4.0%) had diarrhoea (P  0.045). 5 (10.0%) compared 
to 0 (0.0%) had haematamesis  ( P  0.280) and just 4 (8.0%) 
compared to 0 (0.0%) had complained of yellow sclera (P 0.247) . 5 
patients  (10.0%)  and 1 (2.0%) in the control group had dark urine 
(P 0.102) , 1(2.0%) compared to 0(0.0%) had impaired sensorium (P 
0.500)  and no one had pale stool  as shown in table (3.2.1). 
3.2.2.  Presenting signs of the study group:- 
 The clinical signs among the study group were also recorded 
 Pallor was found in 46 patients (92.0%) and 4(8.0%) in the control 
group (P0.00), 48 (96.0%) had normal tempretuure, 2 (4.0%) had 
low temperature and none had high temperature. While in the 
control group, 48(96.0%) had normal temperature 2(4.0%) had high 
temperature and none had low temperature      (p0.063)   
Jaundice was detected in one patient (2.0%) in both groups (P  
0.753). Hepatomegally was present in 5 patients (10.0%) compare 
to 1 (2.0% P0.102) while tenderness in the right hypochondrial was 
elicited in 2 patients (4.0%) compared to 0 (0.0% P 0.247). One 
patient (2.0%) compare to 3 (6.0%) had splenomegally (P  0.309). 
lymph node was palpable in 5 cases (10.0%) in both patients and 
control group  (P  0.630) . 3 (6.0%)  had skin rash,  2 (4.0%) had 
bleeding tendency, but no one in the control group had  neither skin 
rash nor bleeding tendency(P 0.121 , 0.247) and no body had 
confusion, palmar erythema or spider naevi in the two groups .While 
6 children (12.0%)  compared to 1 (2.0%) had cattery marks (P  
0.056)  compare to one (2.0%)  had Tribal marks in both group  as 
shown in table (3.2.2). 
 
 
 
 
 
  
Table 3.2.1: Presenting symptoms of Hepatitis in the  study group 
(n = 100) 
Symptoms Case 
n 
(%) 
 
Control 
n 
(%) 
Total 
n 
(%) 
P.value 
Fever  19 
(38%) 
10 
(20%) 
29 
(58.0%) 
0.038 
Anorexia  24 
(48%) 
02 
(4.0%) 
26 
(23.0%) 
0.00 
Malaise  31 
(62%) 
05 
(10%) 
36 
(72.0%) 
0.00 
Abd. Pain 18 
(36%) 
04 
(8.0%) 
22 
(44.0%) 
0.001 
Nausea 25 
(50%) 
0 
(0.0%) 
25 
(50.0%) 
0.00 
Vomiting  25 
(50%) 
01 
(2.0%) 
26 
(52.0%) 
0.00 
Hematamesis  05 
(10%) 
0 
(0.0%) 
5 
(10.0%) 
0.280 
Diarrhoea  09 
(18%) 
02 
(4.0%) 
1 
1(22.0%) 
0.045 
Constipation 12 
(24%) 
0 
(0.0%) 
12 
(24.0%) 
0.00 
Yellow sclera 03 
(6.0%) 
0 
(0.0%) 
03 
(6.0%) 
0.121 
Pale stool 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0.00 
Dark urine  05 
(10%) 
01 
(2.0%) 
06 
(12.0%) 
0.102 
Yellow sclera 02 
(4.0%) 
0 
(0.0%) 
02 
(4.0%) 
0.247 
Impaired sensation 01 
(2.0%) 
0 
(0.0%) 
0 
1(2.0%) 
0.500 
 
Table 3.2.2: Clinical signs of  Hepatitis in the study group  (n = 100) 
Signs Case Control Total P. value 
n 
(%) 
 
n 
(%) 
n 
(%) 
Pallor  46 
(92%) 
04 
(8%) 
50 
(100%) 
0.00 
Jaundice 01 
(50.0%) 
01 
(2.0%) 
02 
(52.0%) 
0.753 
Temp.  
Normal  
Low  
High  
 
48 
(96%) 
02 
(4.0%) 
0 
(0.0%) 
 
48 
(96%) 
00 
(0.0%) 
02 
(4.0%) 
 
96 
(100%) 
02 
(4.0%) 
02 
(4.0%) 
 
 
 
0.063 
Hepatomegaly  05 
(10.0%) 
01 
(2.0%) 
06 
(12.0%) 
0.102 
Rt.Hyboconderial tenderness  02 
(4.0%) 
00 
(0.0%) 
02 
(4.0%) 
0.247 
Splenomegaly 01 
(2.0%) 
03 
(6.0%) 
04 
(8.0%) 
0.309 
Lymphadenopathy 05 
(10.0%) 
05 
(10.0%) 
10 
(20.0%) 
0.630 
Skin rash 03 
(6.0%) 
0 
(0.0%) 
03 
(6.0%) 
0.121 
Bleeding tendency  02 
(4.0%) 
0 
(0.0%) 
02 
(4.0%) 
0.247 
Tribal marks 01 
(2.0%) 
01 
(2.0%) 
02 
(4.0%) 
0.753 
Confusion 0 
(0.0%) 
00 
(0.0%) 
0 
(0.0%) 
 
Palmar erythema  0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 
Spider naevi  0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 
Cattery marks  06 
(12.0%) 
01 
(2.0%) 
07 
(14.0%) 
0.056 
3.2.3. Significant past medical history in the study group:- 
 The past medical history of the study group showed that nine 
patients (18.0%)   had past history of jaundice compare to 11  cases 
(22.0%) of the control ,3 (6.0%)  compared to 1 (2.0 %) had jaundice 
after transfusion, 11 (22.0%)  compared to 8 (16 .0%) had contacted 
jaundiced patient and  9 (18.0%)  compared to 0(0.0%) had 
experienced hepatitis in the past . Thirty (60.0%) compared to 16 
(32.0%) were hospitalized and 49 (98.0%) compared to 35 (70.0%) 
were operated before for different causes. Twenty three patient 
(46.0%) compared to 0(0.0%) received HBV vaccine, 36 (72.0%) 
compared to 0 (0.0%) received blood transfusion and 2 (4.0 %) 
compared to (0.0%) had history of reused injections as shown in 
table (3.2.3). 
3.2.4. Significant family history in the study group:- 
 The family history of the study group showed that jaundice 
was present in 8 patients (16.0 %) with (CRF) while absent in 42  
(94.0%). In Contrast, it was present in 14 (28.0%) and absent in 
36(72.0%) of the control group (P0.028). History of hepatitis was 
found in 5 patients (10%) with (CRF) and absent in 45(90.0%), while 
it was not found in any case in the control group (P 0.028) as shown 
in (Fig3.2.4) 
 
Table 3.2.3: Significant past medical history in the study group 
 
Past history (P.H) 
Case 
Frequency (%) 
Control 
(%) 
P-Value 
+ve 0 
(0.0%) 
0 (0.0%) P.H of jaundice 
-ve 09 
(18.0%) 
11 
(22.0%) 
 
0.669 
+ve 0 
(0.0%) 
0 
(0.0%) 
P.H of appearance of jaundice after 
transfusion  
-ve 03 
(6.0%) 
01 
(2.0%) 
 
0.882 
+ve 0 
(0.0%) 
00 
(0.0%) 
Contact with jaundice patient  
-ve 11 
(22.0%) 
80 
(16.0%) 
 
0.605 
+ve 0 
(0.0%) 
0 
(0.0%) 
P. H of hepatitis  
 
-ve 09 
(18.0%) 
0 
(0.0%) 
 
0.669 
+ve 02 
(4.0%) 
0 
(0.0%) 
HBV vaccine  
-ve 21 
(42.0%) 
0 
(0.0%) 
 
0.207 
+ve 01 
(2.0%) 
0 
(0.0%) 
P.H of hospitalization 
-ve 29 
(58.0%) 
16 
(32.0%) 
 
0.645 
+ve 02 
(2.0%) 
0 
(0.0%) 
P.H of operation  
-ve 47 
(94.0%) 
35 
(70.0%) 
 
0.960 
+ve 01 
(2.0%) 
0 
(0.0%) 
P.H of blood transfusion 
-ve 35 
(70.0%) 
0 
(0.0%) 
 
0.486 
 
 
 
Figure 3.2.4: Family history of jaundice among study group 
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3.3. Distribution of children in the study group:-  
 The majority of children 33 (33.0%) were on haemodialysis 
while 11 (11. 0%) were on intermittent peritoneal dialysis, 6 (6.0%) 
were on conservative and 50 (50.0%)  cases were the control group 
as shown in Fig (3.3). 
3.3.1. Patients distribution  according to their dialysis center:- 
 The majority 16 patients (48.5%) were dialyzed in Khartoum 
North Hospital, 15 (45.5%) were undergone dialysis in Dr. Salma 
Kidney Dialysis and Transplantation Center (DS.KDTC), 6 (18.20%) 
in Soba University Hospital, 2 (6.1%) in Umm Dorman Military 
Hospital and 1 (3.0%) in Khartoum Teaching Hospital as shown in 
Fig (3.3.1). 
3.3.2.   Prevalence of anti-HCV in relation to risk factors:-   
3.3.2.1. Prevalence of anti-HCV in the different study groups:- 
 Two patients (6.1%) were positive for anti HCV antibodies in 
the haemodialysis group while all the peritoneal, conservative and 
control group were negative (P 0.00) as shown in Fig (3.3.2.1). 
3.3.2.2. Prevalence of anti HCV in relation to the duration on              
hemodialysis:- 
 The majority ,12 patients (36.0%) were on haemodialysis for 
Less than 6 months  and all were negative, 6 (18.2%) were dailysed 
for a period of 6 months - < 1yr and only 1 of them (16.7.0%) was 
positive for anti-HCV antibodies, 3 patients (9.0%) were dialysed for 
1-2 years  and were negative .Eleven patients (33.0%) were on 
dialysis for 2- 4 yrs  and only one  of them(9.0%) was positive and 
one was dialyzed for more than four years however was  negative  
(P  0.003) as shown in Fig (3.3.2.2). 
3.3.2.3.  Prevalence of anti HCV in relation to the number of 
dialysis centers:- 
  Uni-center and multi-centre dialyzed patients  were also 
studied in relation to anti- HCV positivity. The majority of the 
patients;25 (75.8%)  undergone dialysis in single center and 2 
(8.0%) of them were positive, while 8 (24.2%) were dailyzed in 
multiple centers  and no one was positive   (P  0.00) as shown in Fig 
(3.3.2.3) . 
 
 
 
 
 
 
 
 
 
Figure 3.3 :Study groups Distribution     (n=100) 
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Figure 3.3.1:Patients Distribution  according to their dialysis 
centers      (n = 33) 
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Figure 3.3.2.1: Prevalence of Anti- HCV    in the different study 
groups 
(n = 100) 
31
11
6
50
0
5
10
15
20
25
30
35
40
45
50
hemodialysis peritoneal dialysis conservatives control
Series1
Series2
 
 
 
 
 
 
 
 
 
 Figure 3.3.2.2: Prevalence of anti- HCV according to dialytic age 
groups ( n=33) 
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Figure 3.3.2.3: Prevalence of anti HCV  according to the number 
of dialysis centers (n=33) 
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3.3.2.4.  Prevalence of anti HCV  and the blood transfusion:- 
  Anti- HCV positive  patients in relation to their blood transfusion 
status was studied and it shown that;  thirty nine patients (78.0%) out of 50 
transfused with blood, 2  of them (5.1%) were positive. 11 patients (22.0%)  
neither had transfused  nor  anti-HCV  positive  (P  0.00) as shown in 
table(3.3.2.4) . 
3.2.2.5. Prevalence of anti-HCV and the Blood Screening 
Status:-  
 Anti-HCV positive  patients in relation to blood screening  
status showed that;  
thirty six patients (92.3%) out 50 cases transfused with  screened 
blood , 2 of them (5.6%) were positive. Three patients just (7.7%) 
transfused with non-screened blood and fortunately enough they 
were all negative for anti-HCV ( P 0.001) as shown in (table 3.3.2.5). 
3.3.2.6.  Prevalence of anti- HCV and the units of blood:- 
 Anti-HCV positive patients in relation to the number of   blood 
units was studied and it is found that; 
 Six patients (15.4%) received one unit, 10 (25.6%) received 2 
units, 5 (12.8%) received 3 units, 3 (7.7%) received 4 units, 14 
(35.9%) received 5 units, 1 (2.6%) received 8 units. all were 
negative apart from two patients; 1 (10.0%) from the group that 
received 2 units (10.0%) and the other who received 8 units (100% 
P 0.001)  as shown in table (3.3.2.6) . 
3.3.2.7. Prevalence of anti-HCV and the Significant Past history 
of blood transfusion:- 
 Anti- HCV positive patients in relation to the past history of 
transfusion.   
 Thirty seven patients (72.0%) out of 50 were transfused in the 
Past, two  of them (5,1%) was positive now ,while 11 patients 
(28.0%)  were never transfused and they were all negative . (P  
0.00) as shown in table (3.3.2.7). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 3.3.2.4:   Prevalence of anti-HCV and the blood transfusion 
(n = 50  ) 
Blood transfusion Positive 
n 
(%) 
Negative 
n 
(%) 
Total 
n 
(%) 
Yes 02 
(5.1%) 
37 
(94.9%) 
39 
(100.0%) 
No 0 
(0.0%) 
11 
(100.0%) 
11 
(100.0%) 
Total 02 
(4%) 
48 
(96%) 
50 
(100%) 
(P   0.00) 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.3.2.5:  Prevalence of anti-HCV and the blood screening status 
n = (39) 
Screened blood HCV 
Positive freq.         Negative freq. 
(%)                         (%) 
Total 
 
(%) 
Yes 02 
(5.5%) 
34 
(94.5%) 
36 
(100.0%) 
No 0 
(0.0%) 
03 
(100%) 
03 
(100.0%) 
Total  02 37 39 
 
(P  0.001)   
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3.3.2.6:   Prevalence of anti- HCV and the units of blood 
Group 
case 
1 units 
n 
(%) 
2 units 
n 
(%) 
3 units 
n 
(%) 
 
4u nits 
n 
(%) 
5 units 
n 
(%) 
8 units 
n 
(%) 
Total 
n 
(%) 
HC 
+ve 
0 
(0.0%) 
1 
(10.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
01 
(100.0%) 
02 
HC –
ve 
06 
(100.0%) 
09 
(90.0%) 
05 
(100.0%) 
03 
(100.0%) 
14 
(100.0%) 
0 
(0.0%) 
37 
Total 06 
(100.0%) 
10 
(100.0%) 
05 
(100.0%) 
03 
(100.0%) 
14 
(100.0%) 
1 
(100.0%) 
39 
 
(P  0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3.2.7: Prevalence of anti- HCV and the past history of blood 
transfusion 
 
P. blood transfusion HCV +ve 
n 
(%) 
HCV –ve 
n 
(%) 
Total 
n 
(%) 
Yes 1 
(2.8%) 
35 
(97.2%) 
36 
(100.0%) 
No 1 
(76.9%) 
13 
(23.1%) 
14 
(100.0%) 
Total 2 
(4%) 
48 
(96%) 
50 
(100.0%) 
 
(P  0.486) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.Socio-demographic characteristic of seropositive group:_  
3.4.1. Age distribution of seropositive group:- 
 The distribution of  seropositive group according to their age.  
Two patients (6.9%) in the age group 12-18 were positive, while all 
patients in the age group 6 - < 12 yrs and 6 years or less, were 
negative for anti-HCV. No one was positive in all  age groups in the 
control group  (P 0.00) as shown in table (3.4.1).  
3.4.2. Gender distribution of the seropositive group:- 
 The distribution of seropositive group according to their 
gende;One patient (3.0%) out of 33 (66.0%) male was positive for 
anti-HCV antibody. On the other hand, 1 patient (5.9%) out of 17 
(34.0%) female was positive. However, both males and females in 
the control group were negative ( P  0.00) as shown in table (3.4.2).  
3.4.3. Educational level of the seropositive group:- 
 The distribution of seropositive group according to their 
educational level. 
 One patients (10.0%) out of 10 (20.0%) who were secondary 
school educated was positive, 1 (2.7%) out of 37 (74.0%) who were 
primary school educated was positive and zero (0.0) were positive in 
patients who were illiterate, post-secondary school and Quran 
Educated  (P  0.542) as shown in table (3.4.3). 
3.4.5. Residence of seropositive group:-  
 The distribution  of seropositive group according to their 
residence. 
 One patient(5.6%) out of 18 (36.0%) who reside in rural area 
was positive, and 1 (1.1%) out of 9 (18.0%) was positive  in the   
group that reside in sub-urban areas. No one from urban areas was 
positive (P 0.324) as shown in table (3.4.4) 
3.4.6. Fathers’ and mothers’ educational level in the  
seropositive group:- 
 The fathers’ and mothers’ educational level among seropsitive 
group. 
 The two positive patients (12.5%), their father’s and mother’s 
were primary school educated (P 0.351 for both) as shown in table 
(3.4.5a &3.4.5b). 
3.4.7. Fathers’ occupation  in the seropositive group:- 
 The two positive patients (13.3%) their father’s were unskilled 
labourer and no positive cases among the other occupational groups  
(P 0.302) as shown in table (3.4.6). 
 
 
 
 
 
 
Table 3.4.1: Age distribution of seropositive group 
 
Group 6 years or less 
n 
(%) 
 
6 - < 12 
n 
(%) 
12 – 18 
n 
(%) 
P. value 
+ve 0 
(0.0%) 
0 
(0.0%) 
2 
(6.9%) 
Case 
-ve 6 
(100.0%) 
 
13 
(100.0%) 
29 
(93.1%) 
Total  6 
(100.0%) 
13 
(100.0%) 
31 
(100.0%) 
 
0.00 
+ve 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
Control 
-ve 3 
(100.0%) 
18 
(100.0%) 
29 
(100.0%) 
Total  3 
(100.0%) 
 
18 
(100.0%) 
29 
(100.0%) 
 
 
 
 
 
 
 
 
 
Table 3.4.2: Gender distribution of seropositive group 
 
Group Female 
n 
(%) 
Male 
n 
(%) 
P. value 
Case +ve 1 
(5.9%) 
1 
(3.0%) 
 -ve 16 
(94.1%) 
32 
(97.0%) 
0.00 
Total 17 
(100.0%) 
33 
(100.0%) 
 
Control +ve 0 
(0.0%) 
0 
(0.0%) 
 -ve 17 
(100.0%) 
33 
(100.0%) 
 
Total 17 
(100.0%) 
33 
(100.0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4.3: Educational level among seropositive group 
 Group Illiterate 
 
n 
(%) 
Primary school 
 
n 
(%) 
Secondary 
school 
n 
(%) 
Post-
secondary 
n 
(%) 
Quran 
 
n 
(%) 
P. value 
Case +ve 0 
(0.0%) 
1 
(2.7%) 
1 
(10.0%) 
0 
(0.0%) 
0 
(0.0%) 
 -ve 3 
(100.0%) 
36 
(97.3%) 
9 
(90.0%) 
0 
(0.0%) 
0 
(0.0%) 
Total 3 
(100.0%) 
37 
(100.0%) 
10 
(100.0%) 
0 
(0.0%) 
0 
(0.0%) 
 
 
0.542 
Control +ve 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 -ve 3 
(100.0%) 
29 
(100.0%) 
16 
(100.0%) 
0 
(0.0%) 
0 
(0.0%) 
Total 3 
(100.0%) 
29 
(100.0%) 
16 
(100.0%) 
0 
(0.0%) 
0 
(0.0%) 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4.4: Residence of seropositive group 
Group Urban 
n 
(%) 
Rural 
n 
(%) 
Sub-urban 
n 
(%) 
P. value 
+ve 0 
(0.0%) 
1 
(5.6%) 
1 
(1.1%) 
 
Case 
-ve 23 
(100.0%) 
17 
(94.4%) 
8 
(98.9%) 
Total  23 
(100.0%) 
18 
(100.0%) 
9 
(100.0%) 
 
0.324 
+ve 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 
Control 
-ve 21 
(100.0%) 
6 
(100.0%) 
23 
(100.0%) 
Total  21 
(100.0%) 
6 
(100.0%) 
23 
(100.0%) 
 
 
 
 
 
 
 
 
Table 3.4.5a: Fathers’ educational level among seropositive group 
Group Illiterate 
 
(n 
(%) %) 
 
Primary school 
 
n 
(%) 
Secondary 
school 
n 
(%) 
Post-
secondary 
n 
(%) 
Quran 
 
n 
(%) 
P. 
value 
Case +ve 0 
(0.0%) 
2 
(12.5%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 -ve 9 
 (100.0%) 
14 
(87.5%) 
12 
(100.0%) 
8 
(100.0%) 
5 
(100.0%) 
Total 9 
 (100.0%) 
16 
(100.0%) 
12 
 (100.0%) 
8 
(100.0%) 
5 
(100.0%) 
 
 
0.351 
Control +ve 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 -ve 9 
 (100.0%) 
12 
(100.0%) 
1 
6 (100.0%) 
11 
(100.0%) 
2 
(100.0%) 
Total 9 
 (100.0%) 
12 
(100.0%) 
16 
  (100.0%) 
11 
  (100.0%) 
2 
(100.0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.4.5 b: Mothers’ educational level among seropositive group 
 
Group Illiterate 
 
n 
(%) 
Primary 
school 
n 
(%) 
Secondary 
school 
n 
(%) 
Post-
secondary 
n 
(%) 
Quran 
 
n 
(%) 
P. 
value 
Case +ve 0 
(0.0%) 
2 
(12.5%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 -ve 18 (100.0%) 14 
(87.5%) 
1 
1(100.0%) 
3 
(100.0%) 
2 
(100.0%) 
Total 18 (100.0%) 16 
(100.0%) 
11 
(100.0%) 
3 
(100.0%) 
2 
(100.0%) 
 
0.351 
Control +ve 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 -ve 18  
(100.0%) 
16  
(100.0%) 
11  
(100.0%) 
3  
(100.0%) 
2 
(100.0%) 
Total 18 (100.0%) 16 (100.0%) 11 
(100.0%) 
3  
(100.0%) 
2 
(100.0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 3.4.6: Fathers’ occupation of seropositive group 
Group Professional 
 
n 
(%) 
Civil 
servant 
 
n 
(%) 
Skilled 
labourer 
n 
(%) 
Unskilled 
labourer 
n 
(%) 
Farmer and 
shepherd 
n 
(%) 
 
Workless 
 
n 
(%) 
P. 
value 
Case +ve 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
2 
(13.0%) 
0 
(0.0%) 
0 (0.0%) 
 -ve 0 
(0.0%) 
16 
(100.0%) 
8 
(100.0%) 
13 
(87.0%) 
7 
(100.0%) 
4 
(100.0%) 
Total 0 
(0.0%) 
16 
(100.0%) 
8  
(100.0%) 
15 (100.0%) 7 
(100.0%) 
4  
(100.0%) 
 
 
0.302 
Control +ve 0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
 -ve 7 
(100.0%) 
27  
(100.0%) 
3 
(100.0%) 
6 
(100.0%) 
2 
(100.0%) 
3 
(100.0%) 
Total 7 
(100.0%) 
27 
(100.0%) 
3 
(100.0%) 
6 
(100.0%) 
2 
(100.0%) 
3 
(100.0%) 
 
 
 
 
 
 
 
 
 
 Clinical presentation of seropositive group:- 
Complains of seropositive group:- 
 No one of seropositive cases had fever but anorexia, malaise, 
nausea and vomitting were present in 1(50%).  The 2 (100%)  
seropositive cases didn’t  complain of yellow discoloration . Both the 
two cases (100%)  had pale stool. However, no one mentioned 
constipation, diarrhea, abdominal pain, dark urine and hematamesis 
as shown in table (3.5.1) .  
Clinical signs of seropositive group:- 
 Two (100%) of seropositive cases had pallor . 1 (50%)  had 
palpable spleen . 1 (50%) had bleeding tendency . 2 (100%) had 
normal or low temperature and no one  had high temperature. 
However, jaundice, hepatomegally, right hypochondrial tenderness, 
lymph adenopathy, skin rash, tribal marks, confusion, palmar 
erythema, spider naevi and cautary marks were not clinically evident 
in any case as shown in table (3.5.2).      
 
 
 
 
 
Table 3.5.1: Presenting symptoms of HCV among Seropositive group 
Seropositive 
n                          n 
(%)                      (%) 
 
P. value Complaints 
Yes No  
Fever 0 
(0.0%) 
2 
(100%) 
0.380 
Anorexia 1 
(50%) 
1 
(50%) 
0.735 
Malaise 1 
(50%) 
1 
(50%) 
0.620 
Yellow sclera 0 
(0.0%) 
2 
(100%) 
0.921 
Nausea 1 
(50%) 
1 
(50%) 
0.755 
Vomiting 1 
(50%) 
1 
(50%) 
0.755 
Diarrhea 0 
(0.0%) 
2 
(100%) 
0.633 
Abdominal pain 0 
(0.0%) 
2 
(100%) 
0.405 
Constipation 0 
(0.0%) 
2 
(100%) 
0.574 
Pale stool 2 
(100%) 
0 
(0.0%) 
 
Dark urine 0 
(0.0%) 
2 
(100%) 
0.808 
Hematamesis 0 
(0.0%) 
2 
(100%) 
0.808 
Impaired sensorium 0 
(0.0%) 
2 
(100%) 
0.966 
 
Table 3.5.2:  Signs of HCV infection among seropositive group 
Seropositive 
n                               n 
(%)                      (%) 
P. value Signs 
Yes No  
Pallor 2 
(100%) 
0 
(0.0%) 
0.845 
Jaundice 0 
(0.0%) 
2 
(100.0%) 
0.960 
High temperature 0 
(0.0%) 
2 
(100.0%) 
0.921 
Hepatomegally 0 
(0.0%) 
2 
(100.0%) 
0.808 
Right hypochondrial 
tenderness 
0 
(0.0%) 
2 
(100.0%) 
0.921 
Splenomegally 1 
(50%) 
1 
(50.0%) 
0.040 
Lymph adenopathy 0 
(0.0%) 
2 
(100.0%) 
0.808 
Skin rash 0 
(0.0%) 
2 
(100%) 
0.882 
Bleeding tendency 1 
(50%) 
1 
(50.0%) 
0.079 
Tribal marks 0 
(0.0%) 
2 
(100.0%) 
0.960 
Confusion 0 
(0.0%) 
2 
(100.0%) 
- 
Palmar erythema 0 
(0.0%) 
2 
(100.0%) 
- 
Spider naevi 0 
(0.0%) 
2 
(100.0%) 
- 
Cautari mark 0 
(0.0%) 
2 
(100.0%) 
0.096 
Significant past medical history among serpositive group:- 
 The two (100%)  seropositive  cases had never experienced 
jaundice before, and neither had a history of jaundice after 
transfusion nor a history of contact with  a jaundiced patient. They all 
received HBV  vaccine and no one had hepatitis before. 
One patient (50%) was hospitalized and 2 (100%) were undergone 
operation No one had history of reused injection. On the other hand, 
9 (18.0%) of seronegative group had past history of jaundice, 3 
(6.0%) had a history of jaundice following transfusion, 11 (22.0%) 
experienced  hepatitis, 9 (18.0%) had contacted a jaundiced patient, 
21 (42.0%) received hepatitis B vaccine, 29 (58.0%) had been 
hospitalized, 47 (94.0%) had history of operation and 4 (8.0%) had 
history of reused injection as shown in table (3.5.3)  
Significant family history  among seropositive group:- 
 No one of seropositive group had a family history of jaundice 
or hepatitis while 8 (16.0%) had family history of jaundice and 5 
(10.0%) had history of hepatitis, but all were negative as shown in 
table (3.5.4). 
 
 
  
Table 3.5.3:  Significant past medical   history  among seropositive 
group 
Past history (P.H) +ve 
 
P. value 
 0 (0.0%) P.H of jaundice 
 2 (100.0%) 
 
0. 00 
Yes 0 (0.0%) P.H of appearance of jaundice after 
transfusion  No 2 (100.0%) 
 
0.417 
Contact with jaundiced patient  Yes 0 (0.0%) 
 No 2 (100.0%) 
 
0.00 
P.H of hepatitis  Yes 0 (0.0%) 
 No 2  (100.0%) 
 
0.827 
Screened blood  Yes 2(100.0%) 
 No 0 (0.0%) 
 
0.001 
P.H of hospitalization Yes 1  (50.0%) 
 No 1 (50.0%) 
 
0.00 
P.H of operation  Yes 2 (100.0%) 
 No 0 (0.0%) 
 
0.00 
P.H of reused injection Yes 0 (0.0%) 
 No 2 (100.0%) 
 
0.921 
Received vaccination Yes 2  (100.0%) 
 No 0 (0.0%) 
 
0.00 
  
 
 
 
 
 
 
  
Table 3.5.4: Family history among seropositive group 
 
Family history (P.H) 
Yes 
n 
(%) 
+ve 
No 
n 
(%) 
P. value 
F.H of jaundice 0 
(0.0%) 
2 
(100.0%) 
 
0.607 
F.H of hepatitis 2 
(100.0%) 
 
0 
(0.0%) 
 
 
0.902 
Total                                                      2 
(100.0%) 
2 
(100.0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serology of HCV:- 
Anti- HCV status before the study period:- 
 The control group and patients on conservative management 
were not screened for anti- HCV before this study. 44 patients were 
screened; elevenpatients (22.0%) on peritoneal dialysis and they 
were all negative at the beginning of the study period and they 
remain so and 33(66.0%) haemodialyzsis patients, one  of 
them(3.0%)  was positive for anti- HCV before the study. So one 
patient (2.2%) out the 44 was positive (P 0.00) as shown in table 
(3.6.1). 
Anti- HCV Seroconversion:- 
 The seroconversion of anti-HCV after the study period.The 
haemodialyzed patient (3.0%) who was positive turned to be 
negative at the end of the study period. However, other 2 
haemodialysis patients (6.0%) out of the 33 were negative at the 
beginning turned to be positive  (P 0.324) as shown in table (3.6.2). 
HBV status before the study:- 
 The same as HCV, the control group and the conservative 
were not screened before this study. 44 patients were screened; 11 
patients (22.0%) on peritoneal dialysis and they were negative for 
HBV infection and 33 patients (66.0%) on haemodialysis, 4 of them 
(12.1%)  were positive. So 4 patients(9.1%)  out of the 44 were 
positive  (P 0.00) as shown in table (3.6.3). 
HBV seroconversion:- 
 The seroconversion of HBV after the study period . 
The 4  haemodialyzed  patients (12.1%) which were positive, 2  of 
them became negative and 2 stiII positive while other 4 patients  on 
haemodialysis  were negative at the start became positive now. So a 
total of 6 haemodialysis patients (18.2%) out of  the 33 were positive 
. 
The 11 patients (22.0%) on peritoneal dialysis continued to show the 
same negative result as shown in table (3.6.4). 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6.1: Anti- HCV status before the study period      (n 
= 100) 
Group 
HCV 
Conservativ 
n 
(%)e 
Peritoneal 
n 
(%) 
Haemoialysis 
n 
(%) 
Control 
n 
(%) 
Positive - - 1 
(3.0%) 
- 
Negative - 11 
(100%) 
32 
(97.0%) 
- 
Not screened 6 
(100%) 
-  50 
(100.0%) 
Total 6 
(100%) 
11 
(100%) 
33 
(100%) 
50 
(100%) 
 
(P  0.00) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3.6.2: Anti- HCV Seroconversion 
(n = 100) 
 
 
( P 0.324) 
 
 
 
 
 
 
 
 
 
 
 
HCV during the study HCV before the study 
+ ve 
n 
(%) 
- ve 
- n 
(%) 
Positive - 1 
(1.0) 
Negative 2 
(2.0%) 
41 
(41.0%) 
Not screened - 6 
(6.0%) 
Control - 50 
(50.0%) 
Total 2 98 
 Table 3.6.3: HBV status before the study 
(n = 100) 
Group 
HBV 
Conservative 
n 
(%) 
Peritoneal n 
(%) 
Haemoialysis 
n 
(%) 
Control n 
(%) 
Positive - - 4 
(12.1%) 
- 
Negative - 11 
(100.0%) 
29 
(87.9%) 
- 
Not done 6 
(100.0%) 
- - 50 
(100.0) 
Total 6 
(100.0%) 
11 
(100.0%) 
33 
(100.0%) 
50 
(100.0%) 
 
(P 0.00) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6.4:  HBV seroconversion 
(n = 100) 
HBV during the study HBV before the study 
+ ve 
n 
(%) 
- ve 
- n 
(%) 
Positive 2 
(2.0%) 
2 
(2.0%) 
Negative 4 
(4.0%) 
36 
(36.0%) 
Not done - 6 
(6.0%) 
Control - 50 
(50.0%) 
Total 6 
(6.0%) 
94 
(94.0%) 
(P 0.00) 
 
 
 
 
 
 
 
 
 
 
Correlation of ALT  level to Anti -HCV  status:- 
 The  ALT  level in relation to Anti- HCV  status .One  
patient(2.0%)  out of the 50 patients was positive for Anti -HCV  and 
had high ALT level and 1(2.0%) was positive for Anti HCV and had 
normal ALT Level. 48  (96.0%) had normal ALT level and were 
negative for  anti- HCV . 
 One case  (2.0%) in the control group had high level of ALT 
but it was negative for anti- HCV and 49 (98.0%) were normal for 
ALT and negative foranti- HCV infection (P 0.00) as shown in table 
(3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3.7: Correlation of ALT  level to Anti- HCV status 
(n = 100) 
ALT Case 
n 
(%) 
Control 
n 
(%) 
 
P.V 
High   (+ve) 1 
(2.0%) 
0 
(0.0%) 
(0.000) 
(-ve) 0 
(0.0%) 
1 
(2.0%) 
 
Normal(+ve) 1 
(2.0%) 
0 
(0.0%) 
 
(-ve) 48 
(96.0%) 
49 
(98.0%) 
 
Total 50 
(100.0%) 
50 
(100.0%) 
 
 
(P  0.00) 
 
 
 
 
 
 
 
 
 
HCV  Co-infection:- 
Hepatitis C & B co-infection:- 
HCV&HBV co-infection:-  
  None of the patients was positive for  both C & B .2 patients 
(4.0%) were positive for anti- HCV but negative for B. 6 patients 
(12.0%) were positive for HBV antigen but negative to C  . 42 
(84.0%) were negative for both  and all the  control group were 
negative for B and C as shown in table (3.8.1) . 
HCV & HIV Co- infection:-  
HCV and HIV co-infection:-  
         None of the patients was positive for HCV and HIV, nor  
positive for HIV and negative for the HCV . 2 patients (4.0%) were  
positive for HCV  but negative for HIV. All the control group were  
negative for both as  shown in table (3.8.2) . 
 
 
 
 
 
 
 
 
  
 
 
Table 3.8.1: HCV&HBV Co-infection 
(n = 100) 
Hepatitis B 
Hepatitis C Positive Negative Total 
Positive 0 2 2 
Negative 6 92 98 
Total 6 94 100 
(P 0.158) 
 
 
 
 
 
 
 
 
 
Table 3.8.2: HCV& HIV Co-infection 
(n = 100) 
HIV 
Hepatitis C Positive 
n 
Negative 
N 
Total 
n 
Positive 0 2 2 
Negative 0 98 98 
Total 0 100 100 
 
 
 
 
 

  
Medical management of Anaemia in relation to  Anti-HCV 
status:-   
Anti- HCV status in patients receiving oral iron therapy and/or blood 
transfusion:-  
 The oral iron therapy and blood transfusion in relation to HCV 
status 
 The majority of the patients 45 (90.0%) were receiving iron 
while 5 (10.0%) were not. 27 patients (60.0%)  out of 45 were 
transfused while18 (40.0%)  were not transfused   and all those who 
were not taken oral iron   5 (100.0%) were not transfused ( P0.032) . 
 Two (4.4%) out of the 45 who received  oral iron were anti-
HCV positive vs. 0 (0.0%) out of 5  ( P  0.120) as shown in table 
(3.9.1)   .    
Anti-HCV status in patients receiving parental iron and/or blood 
transfusion:- 
 The parental iron and\or blood transfusion in relation to anti- 
HCV status. 
 Thirty (60%) were taken parental iron vs 20 (40%) were not 
taken. 
 Twenty three (76.7%) out of the 30 (60.0%) vs. 12 (60.0%) out 
of the 20 (40.0%) were transfused while 7(23.3%) vs. 8(40.0%) ( P  
0.019)  .Two (6.7%) out of  the 30 were positive vs. 0(0.0%) out of  
20   (P  0.012) as shown in table (3.9.2). 
Anti-HCV status in patient receiving erythropoietin and/or blood 
transfusion:- 
 The  erythropoietin and blood transfusion in relation to  anti-
HCV status. 
 Twenty-eight (56.0%) were taken EPO vs 22 (44.0%) were not 
taken Epo.  
 Twenty two (78.6%) out of the 28 vs. 5 (22.7%) out of the 22 
were transfused  and 6 (21.4%) vs. 17(77.3%) were not transfused  
(P 0.006). 
 Tow (7.1%) out of 28 of those who were taken EPO were 
positive vs 0 (0.0%) in those who were not taken EPO (P 0.005) as 
shown in table (3.9.3). 
 
 
 
 
Table 3.9.1: Oral iron therapy and blood transfusion in relation to 
anti- HCV status 
(n= 50) 
Oral iron yes Oral iron No Blood translation 
+ve -ve +ve -ve 
Yes 2 25 0 0 
No 0 18 0 5 
Total 2 43 0 5 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9.2: Parental iron and blood transfusion in relation to  anti-HCV 
status 
(n = 50) 
Oral iron yes Oral iron No Blood translation 
+ve -ve +ve -ve 
Yes 2 21 0 4 
No 0 7 0 16 
Total 2 28 0 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9.3: Erythropoietin and blood transfusion in relation to anti- 
HCV status 
(n = 50) 
EPO Yes EPO No Blood translation 
+ve -ve +ve -ve 
Yes 2 20 0 5 
No 0 6 0 17 
Total 2 26 0 22 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION      
General Consideration:- 
Parentally transmitted hepatitis virus infection has always been 
a major health problem in patients with CRF, specially those on 
haemodialysis (17). 
The potential importance of HCV infection in Sudanese 
children has been recently noted with the rate of anti-HCV  about 
16.4% in the polytransfused and  20% in the jaundiced children  vs. 
13% in adult (5). 
Despite these results, few studies were conducted in this field.  
Thus, this study was targeted specifically for CRF patients as 
they are high-risk group, so as to identify the incidence of HCV 
seropositivity among them. 
Characteristics of Anti-HCV positive cases:- 
The total number of anti- HCV positive cases during the study 
period were two cases ( 4.0%). The study showed that this 
prevalence was in the haemodialysis group 2(6.0%) only while no 
positive cases in the peritoneal, conservative or control group. This 
result was significant (p 0.000). 
Higher results were reported from Singapore; (45.0%) (54), 
Brazil (50%) (55), Germany (10.1%) (56), USA (12.0) (57) and Italy 
17.3% (58). 
The prevalence was in the eldest age group; 12 – 18 years, 
most probably longer duration of ill health, adherence and exposure 
to dialysis, blood transfusion, Bilharzias and other risk factors were 
the explanation . This was showed  statistical significance (P  0.00) 
.It  was  similar to what was reported by A. Wahab in Egypt (59), and 
studies conducted in Jeddah (60,61).   
Female to male ratio was 5.9: 3 equal to 1.9. This trend of gender 
was statistically significant (P 0.00) and it was similar to Haren 
Kumar study (17), but it was different from studies conducted 
abroad.(62,63,64)    
The possible explanation might be the normally lower 
hemoglobin level in female and physiological anaemia in the 
pubertal age that may be aggravated by (CRF), so necessitating 
blood transfusion at lower hemoglobin level compared to the male in 
the same age group. 
So there was age and sex difference which were opposite to 
studies reported from India and China(65,66).   
The seroprevalence of HCV were higher among the secondary 
school educated patients than the primary one, (10.0%) vs (2.7%) 
respectively, but this difference was  statistically insignificant 
statistically P 0.542). However, this result could be explained by the 
fact that patients with ESRD are living longer with increased facilities 
and improved techniques of haemodialysis, so they live until they 
enter the school, but they lost there after due to complication of 
ESRD. It was found in this study that the seroprevalence of HCV 
infection was highest (5.6%) in rural than Subarban area, in which it 
was (1.3%) and urban area  (0.0%). Despite this, no statistical 
difference was shown (P 0.324). This could be attributed to non- 
adherence to screening program in rural blood bank. However, this 
result was evident in the study conducted by Dimetri as the majority 
of cases were from El Gezira.25)  
It was evident in this study that the seroprevalence was 
confined to children of un-skilled labourers fathers (13.3%), although 
the relation to the father’s occupation did not show any statistical 
significance, it might be explained by the fact that, those children live 
in  poor conditions, thus became more susceptible to HCV infection, 
also the un-skilled laborers are more subjected to trauma. This was 
in contrast to what was shown by Ngatchu in his study where a 
significant trend was seen.(67)   It was also shown that (14.0%) of the 
seropositive cases  were among primary school educated fathers 
and mothers, but no statistical significance was shown (P 0.351) for 
both. This result was similar to what was found by Dimitri.(25) It was 
justified by  the use of traditional treatment like cauterization , 
among the lower educated parents.  
Clinical patterns of HCV:- 
Regarding presentation among those who showed HCV 
positivity, it was similar to what was stated in the literature, all HCV 
positive were asymptomatic and a febrile, no one had complained of 
yellow sclera, the most evident complain was pale stool, I thought it 
was over prescribed. Anorexia, malaise, nausea and vomiting were 
mentioned in 50%. No one had clinical jaundice, hepatomegally, 
right hypochondrial tenderness, Cautery marks or any signs of 
chronic hepatitis or chronic liver disease. Pallor was evident in all 
patients; which is most probably is due to their CRF. Bleeding 
tendency and splenomegaly were evident in some of seropositive 
patients. This asymptomatic presentation was reported by Tong in 
USA.(68) However, Roberts reported that approximately 20% of HCV 
infections were symptomatic (69). Another study(70) showed  that the 
onset of HCV infection is often un-recognized, and the early course 
of  the disease is often indolent and acute hepatitis with an icteric 
phase was rare and occurs only in (15%-20%) of infections. 
However, the infection leads to chronicity. Clinical diagnosis based 
on signs and symptoms was very difficult to attain, since in most 
cases, the infection was asymptomatic.  
Risk factors of HCV in CRF:- 
The study revealed that, prevalence confined to the 
haemodialysis population  which was (6.1%)  (P 0.00). Although it 
was lower compared to (70%) for KSA (71) and (75%) for  Egypt (72). 
But it was nearer to those results seen in Spain, Germany and the 
UK where the prevalence of anti-HCV  was ( 20%), (5.5%) and 1% 
respectively.(73)  
This lower prevalence could be attributed to possibly good 
application of universal precaution in these centers. In this study the 
prevalence was (8.7%) in single center dialysis while (0.0%) in muti-
center  dialysis. Although the trend  toward single-centre dialysis 
was  significant statistically (P 0.00) ,it was in contra distinction to 
what has being reported in Abu El-Gasim study’s (74); where the 
trend was toward   multi-center dialysis. 
The study done by Abdulla Mohammed(75) revealed that (78%) 
of those who utilized more than one center acquired HCV infection, 
compared to (64.3%) in those who were exclusively treated at single 
center and the same conclusion was drawn out from  a  study done 
in UAE.(76) 
 Another study carried out in the KSA(77), also showed this 
positive relationship between multi center dialysis and acquisition of 
HCV infection even among patients who were not transfused. 
 The study also, revealed increased prevalence which was 
(10%)-(20%) with increased duration on haemodialysis. Statistically   
it    was a very significant result (P 0.003) and it was compatible with 
the result of others studies.(75)  Multi varate analysis(74) has revealed 
that seropositivity of HCV infection increases with longer dialytic 
age. Our figure were nearer to those reported from Germany 
(14%)(56) , Japan 14%(78) and Italy (26%).(79) 
Various factors implicated for this high frequency are the cross 
infection through the use of common equipment, extra corporeal 
Haemocirculation ,immunocompromised state, contact with an 
infected person and contamination of environmental surfaces, 
gloves, clamps and dressing.(62,80,81)  
So duration on HD is considered one of the important risk 
factors for acquiring HCV infection, the mean age on HD among 
anti-HCV antibodies positive cases was 15 months in this study 
which was higher than   HCV negative patients (6 months).This 
result in agreement with a study conducted in  Elmadina 
Almunawara  (82)  where they found that the duration on  HD  was 
longer in  Anti -HCV   positive group than in the negative group ,the 
same result was in Taiwan and Qatar.(83,84,85)       
 However, in a study conducted in  Spain(86), the mean age on  
HD  didn’t showed statistical significance differences  between sero 
converter and non – sero convertes;36 vs 35months respectively .  
The study revealed that Blood transfusion was another risk 
factor for acquiring HCV infection as it showed 5.1%seropositivity 
among blood transfused patients vs. (0.0%) among non-transfused. 
So (100%) of seropositive group were transfused, (p 0.00) 
statistically significant . 
This finding was in agreement with studies done in Kuwait(60), 
UAE(76) and Netherlands(87) where the prevalence of anti- HCV 
antibodies was higher in patients who received blood transfusion It 
is also supported by another study conducted   in 102 hospital in 
KSA(71) where they found a positive  correlation between  annual 
incidence of anti-HCV seroconversion and history of blood 
transfusion  but   no correlation with the number or frequency of  
blood transfusion  was found. 
However, in studies carried out in Jeddah(61) and the western 
province of Saudi Arabia(88)  no association between anti –HCV  
positivity  and blood transfusion was found. This study showed that , 
the trend of seropositivity  was towards frequent blood transfused 
patients; (10 % )of seropositivity among those who were received 
2units while reaching (100%) among those who  received 8 units, (P 
0.00) highly significant and similar result had been reported by many 
other investigator. (89,90,91,92) 
On the other hand, our study showed no single case with 
positive anti-  HCV anti bodies received non screened blood and the 
4.3% positive cases all were received screened blood transfusion, 
(P 0.001) was  significant.    
 However this lower prevalence (5.1%)among blood 
transfused could be explained by application of screening program 
for the blood and it is products for anti-HCV anti bodies in the blood 
bank (93). Nevertheless, another study(84) showed that 65 of 97 
patient on HD (67%) who had not received previous blood 
transfusion had positive anti-HCV antibodies, a finding which 
indicates that factors other than blood transfusion was contributing 
to the transmission of HCV infection.  
Other investigators(61,84,94)  also found no correlation between 
blood transfusion and positive anti-HCV antibodies and they had 
suggested that the association between dialysis - associated 
hepatitis and transfusion was not causal but it was rather related to 
duration on HD. 
The study showed that seropositivity was the same among 
patients who had past history of transfusion and those who had not, 
(P 0.486) which was significant. 
Significant past medical and family history:- 
  The study showed no history of transfusion hepatitis in sero- 
positive cases as they never experienced jaundice, (P  0.00) was 
significant nor jaundice following transfusion, (P 0.417) was not 
significant statistically .This points was mentioned by Juneja in his  
study(95) where HCV positivity was 57% in this group of patients. 
 More over, the study showed that none of the HCV positive 
cases had contacted jaundiced patients and (P 0.00 )  statistically 
significant . 
This finding was not corresponding to what was found by El 
Faleh and Khalifa in their study (96,97) where the prevalence was 
about 15% among those who had positive history of contact. 
In addition, the study showed that past history of hepatitis was 
not existed in seropositive cases, (p.0.827) was insignificant. 
 This was in contradistinction to what was reported in other 
study(5), but the explanation could be the small sample size . 
 Also, history of hospitalization was present   in   (50%) of 
seropositive cases (p0.00), which was statistically significant. 
 It is clear that hospital admission is a risk factor for 
nasocomial infection. History of operation was present in 100%of 
seropositive cases and the (p 0.00), very significant statistically and 
it was similar to  Alfaleh and Khalifa studies’s  (96,97,98) . Specifically 
speaking history of cauterization as minor operation was not found  
in seropositive cases, however, it was present   in 52 of 
seronegative and the (P 0.096) . 
The result also showed that family history of jaundice and 
hepatitis were not significant statistically (P 0.607) & (P 0.902) 
respectively    .                       
Liver enzyme(ALT) &anti- HCV seropositivity:- 
ALT level was found to be high in 50% of seropositive (P 
0.00), highly significant, so our result in agreement to what 
mentioned in numerous reports regarding correlation between 
serum ALT level and anti-HCV positivity (83,89). However more recent 
report did not  find any such correlation and elevated ALT levels 
were found in  (24%) - (67%) of dialysis patients with positive anti- 
HCV antibodies(99,100) and even when HCV-RNA studied , elevated 
ALT was found in only (31%) of those patients and  in (30% ) of 
those who had biopsy proven hepatitis.(111)      
Postulated reasons for this correlation are depressed  baseline 
ALT level in patients on haemodialysis(102), some of anti-HCV 
positive patients may have cleared the infection and seropositiviy 
may be the remnant evidence of past infection (103) and the positivity 
may also reflect viral replication occurring at extra hepatic sites (104)  
or infection caused  by none virulent HCV  strains. Other studies 
showed that serum ALT levels are poor predictors of  liver 
disease.(101,104,105)  However, it had been shown that the greater 
elevation in liver enzymes the higher the probability of histological 
evidence of liver disease.(105) 
Serum ALT, the  most  reliable of the liver test is associated 
with fluctuation  during the chronic stage of HCV infection .As high 
as (30%)  of chronic HCV patients may fall within the normal range 
of serum ALT despite significant liver disease.(106,107) Another 
study(108) concluded that HCV-related liver disease is more benign in 
HD patients, suggesting that Hepatocyte growth factor (HGF) serum 
level attained during dialysis would attenuate the liver damage 
caused by HCV.(109,110)   Previous study showed that HD is a potent 
stimulus to HGF which accelerates liver repair and it suppresses 
HCV-induced apoptosis,   so they came out with the possible future 
therapeutic use of HGF in chronic hepatitis C.(111) Rampnio et al(112) 
observed that milder histological lesion in patients receiving HD in 
comparison  to patients with normal renal function. 
Prevalence of HBs -Ag in CRF patients in our study was 6 
patients(12%) which is higher than HCV which was  2 patients 
(4.0%).It was in accordance with the result of other studies (113). This 
fact is expected for many reasons, first, the prevalence of  HBV is 
higher than the prevalence of HCV. Second, the viraemia of HBV is 
higher than that of HCV, so the transmission of HBV is easier and 
more effective than that in the case of HCV transmission from 
patients to health people. However, the prevalence was just (3%) in 
study done in Bahrian.(114)                                                                                         
HCV Co- infections:- 
The result showed no one of seropositive cases had  existing 
HBV co-infection nor HIV   (P. 0.158 )  ,although  insignificant  it was 
similar to study done in Syria.(115)    
Drug management and/or blood transfusion and it is relation to 
HCV seropositivity:- 
The study showed that 40% of patients who were taken oral 
iron were not transfused. In additional to this, non-transfused 
patients were seronegative, so oral iron therapy is important in 
reducing blood transfusion which is one of the risk factor for HCV 
infection. While 23.3% of patients who were taken parental iron were 
not transfused  and  22% of patients who received EPO were not 
transfused, there was no similar study done in  this aspect . 
Our study showed that blood transfusion was still higher 60% 
among those who were taken oral compare to 0.0%among those 
who were not taken iron (P  0.032), also 76.7 % of those who were 
taken parentral iron were transfused vs 60% among those who were 
never receive parentral iron (P 0.019)  was significant. Furthermore, 
it account for 78% of patients who received Epo vs 29% of those 
who did not received Epo (P 0.006), it was significant. In both 
groups, the non-transfused patients were negative for Anti-HCV. 
So still medical treatment did not replace blood transfusion in 
management of  anaemia in CRF  patients who were at risk . 
 
 
   
 
 
 
 
 
 
 
 
CONCLUSION 
• The prevalence of anti –HCV antibody among CRF patients on 
haemodialysis was 6.1%. 
• No co-existing HIV or HBs antigen  anti-HCV positive children 
with CRF. 
• The main risk factors are;  haemodialysis, its duration, and 
frequent history of blood transfusion. 
• Socio demographic factors didn’t reveal any difference 
between the study groups. 
• History of jaundice, hepatitis and post transfusion jaundice 
were not significant. 
• However, history of surgical operation was significant. 
• Seropositive group were clinically a symptomatic. 
• Liver enzyme (ALT) was a predictor of infection in half of sero 
positive patients. 
• The prevalence of HBV antigen was 12.0% in the Haemo 
dialysis patients. 
  
 
 
 
RECOMMENDATIONS 
• Screening for children who were transfused with blood 
before 1992, and those who received clotting factors before 
1987. 
• Use of EPO in mangment of anemia due  chronic renal 
disease.  
• Confirmatory assay like recombinant immunoblot assay 
(RIBA) and polymerase chain reactions (PCR) should be 
made available. 
• Estimation of transaminase levels in all dialysis patients 
should be done routinely. 
• Patients showing persistently raised levels of ALTs and are 
anti- HCV antibodies positive must be dialyzed separately. 
• Adaptation of strict disinfection protocols and universal 
precautions in every dialysis unit, will reduce the cost 
effectiveness in stead of discontinuing reuse of dialyzer. 
• Automation in dialyzer reprocessing can go along way in 
limiting the spread of hepatitis C viral infection. 
• Conduction of further studies in high-risk group and blood 
donors so that true incidence is established. 
• Prospective studies in the issue of the pathogenicity of the 
different genotypes and subtypes are required to determine 
the epidemiology of HCV genotype.  
• Evidence based strategy for the management of HCV liver 
diseases. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
1) Huhta JCL. Chronic renal failure.  In: McMillan IA, De Agelis 
CD, Feigin RD, Warshaw JB (editors).  Oski’s Pediatrics:  
Pediatrics Principal and Practice, 3rd Ed. Philadelphia; Lippincot  
Williams and Wilkins: 1999. P. 1726. 
2) Levey AS, Coresh J, Balk E: National Kidney Foundation 
practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. Ann Intern Med 2003 Jul 15; 
139(2): 137-47[Medline].  
3) Scharer K. Incidence and courses of chronic renal failure in 
childhood. Proc Europ Dialysis Transplant Assoc 1971; 7: 211. 
4) Purcell RH, Alter HJ. Pattern and pathogenesis of hepatitis C 
virus. 37th Annul meeting of the infectious disease society of 
America.  Philadelphia; 1999. Session 70: S 110. 
5) Sakran MH. Prevalence of Hepatitis C Virus in high risk 
Sudanese children in Khartoum state. MD Thesis. University of 
Khartoum; Sudan: 2000. 
6) Riyad AS, Yousef YH, Nabil SM, Mohammed SR. Hepatitis C 
virus infection in hemodialysis patients in Jordan.  Saudi Med J 
2003; 2(24): S137. 
7) Mohammed AD, Mohamed AE, Aisha MD, Mansour M, Werfalli 
AA et al. Prevalence of Hepatitis C virus antibodies among 
different populations of relative and attributable risk. Saudi Med 
J 2003; 2 (24): 137. 
8) Yassin IE, Shakunthala V, Bari MZ, et al. Hepatitis C virus 
infection among dialysis patients in the United Arab Emirates. 
Saudi Med J 2003; 2 (24): S134. 
9) Aboud O, Rashid A, Al-Kaabi S. Hepatitis C virus infection in 
hemodialysis patients in Qatar. Saudi Med J 2003; 2 (24): 135. 
10) WHO.  Hepatitis C virus. Saudi Med J 2003; 2 (24): 102. 
11) Bakir TM.   Age specific prevalence of antibody to Hepatitis C 
virus among the Saudi population. Saudi Med J 2003; 2 (24): 
S120. 
12) Omar MN, Mohammed AT, El-Tonsy A. Prevalence of hepatitis 
C virus antibody. Saudi Med J 2003; 2(24): S122. 
13) Jonas MM, Zilleruelo GE, Larve SI. Hepatitis C infection in 
paediatric dialysis population. J Pediatr 1993; 89: 707-9. 
14) Kleter GE, Brouwer JT, Heijtink RA, Schalm SW. Detection of 
hepatitis C virus RNA in patient with chronic hepatitis C virus 
infection. Anti Microbiol Agents Chemother 1993; 37: 595-97. 
15) Megmar AS, Martins RM, Sheila AT, Simonne AS, Carmen LL 
et al. Hepatitis c prevalence and risk factors in haemodialysis 
patients. File://a:/HIND9.HTM  
 
16) Oliva JA, Maymo RM, Carrio J, Oelgard D, Mall JM. Late sero 
conversion of c virus markers in haemodialysis patient.  Kidney 
Intern 1993; 43: 5. 
17) Haren K, Naqui SA, Ahmed A, Hamid S. Hepatitis c virus 
antibodies (Anti HCV) in haemodialysis vs non-dialysis patients. 
Kidney Int 1994; 2 (44): 35-6. 
18)  Snyder   DJ , Pickering  KL . Hepatitis A & E. In:  Behrman RE, 
Kliegman RM, Arvin AM, (editors). Nelson Textbook of 
Pediatrics, 15th ed. Philadelphia; WB Saunders: 1996. P.             
1609-1611.  
19) Betts PR, Mc Grath G.  Growth pattern and dietary intake in 
children with chronic Renal Insufficiency. Br Med J 1972; 2:189. 
20) Cameron S, Jean AD, David PG, Ritz E. Haemodialysis, 
complication during haemodialysis and adequacy of 
haemodialysis. In: Cameron S, Jean AD, David PG, Ritz E 
(editors)  Oxford Text Book of Clinical Nephrology, 2nd Ed.  New 
York; Oxford University Press: 1992: 1418-1439. 
21)   Henryh HS, Stephn M, Hoofnagle J.  Acute viral hepatitis.  In: 
 Henryh HS, Stephn M, Hoofnagle J (Editorials) Oxford Clinical 
Textbook of Infectious Diseases. Principal and Practice, 1st Ed.  
New York:; Churchill Livingstone: 1995. P.1184-1186. 
22) A-Kader HH, Balistreri WF.  Hepatitis C virus: implications to 
pediatric practice. Infect Dis J 1993; 12:853-67. 
23) Choo QL, Kuo G, Weiner A. Isolation of CDNA clone derived 
from blood borne-non-A, non-B viral hepatitis genome. Science 
1989; 244: 359-62. 
24) Houghton M, Weiner A, Han J, Kuo G, Choo QL. Molecular 
biology of the hepatitis C viruses: Implications for diagnosis 
development and control of viral disease. Hepatol 1991; 14: 
381-88. 
25) Dimitri ME, Kadaru AG El-Tigani A. Prevalence of hepatitis C 
virus antibody and associated B virus markers among 
Sudanese patients with acute viral hepatitis in Khartoum. MD 
thesis. University of Khartoum, Sudan 1996.  
26) Nowicki MJ, Balistreri WF. The hepatitis C virus: Identification, 
epidemiology and clinical controversies. J Pediatr Gastroenterol 
Nutr 1995; 20:248-74. 
27) Garson JA, Tedder RS. The detection of hepatitis C infection. 
Rev Med Virol 1993; 3: 75-83 .      
28) Esteban JI, Genesca J, Alter HJ. Hepatitis C molecular biology, 
pathogenesis, epidemiology clinical features and prevention. 
Progress Liver Dis 1992; 10: 253–82. 
29) Simmonds P, Alberti A, Alter HJ. A proposed nomenclature of 
hepatitis C viral genotypes. Hepatol 1994; 19: 1321-323.  
30) Kumar  U, Monjardino J, Thomas HC Hypervariable region of 
hepatitis C virus envelope glycoprotein (E2/NS1) in a 
gammaglobulinemic patients. Gastroenterology 1994; 
106:1072-75. 
31) Mahaney K, DiBisceglie AM, Hoofnagle JM, Sallie R. Genomic 
variability of the hepatitis C virus development of mutations 
during antiviral therapy. Hepatology 1993;18: 92. 
32) Kao JH, Chen PJ, Lai MY, Chen DS. Super infection of 
heterologus hepatitis C virus in patients with chronic type C 
hepatitis. Gastroenterology 1993; 105: 583-87. 
33) Hayashi N, Hagiwara H. Viral factors affecting outcome of 
hepatitis C virus infection. Viral Hepatitis 1996; 2:187-98. 
34) Barrakat  S,  Fedail  SS, EI- Tigani A .  Hepatitis B and C in 
hepatocellular carcinoma. MD Thesis, University of Khartoum, 
Sudan 1998. 
35) Takada N, Takase S. HCV genotypes in different countries. J  
Hepatol  1993;17: 277-83. 
36) Lefkowitch JH, Schiff    ER, Davis  GL, Perrillo RP, Lindsay  K, 
Bodenheimer  HC et  al. Pathological diagnosis of chronic 
hepatitis C: a multi center comparative study with chronic 
hepatitis B.  Gastoenterology 1993; 104: 595-603. 
37) Scheuer PJ, Ashrafzadeh P, Sherlock S. The pathology of 
hepatitis C.  Hepatology 1992; 15: 567-71. 
38) Hess G, Massing A, Rossol S. Hepatitis V virus and sexual 
transmission. Lancet 1989; 2: 987. 
39) Bhandari BN, Wright TL. Viral hepatitis.  Current diagnosis and 
treatment. California: Appleton and Lange 1996: 484-94. 
40) Martin  P, Bernstein D,  Alter  M. The natural history of hepatitis 
C: an evolving story, prognostic factors, disease progression 
and long–term burden.  Digest Dis 2000; (13): 63-5. 
41) Thaler MM. Hepatitis C in infants and children. Curr Opin  
Pediatr  1997: 508-12. 
42) Neal  AH, Jon SA. Hepatitis C virus infection. J Pediatr 1998; 
101(3): 481-85. 
43) Wang JT, Wange TH, Shev JC, Lin JT, Chen DS. Hepatitis C 
virus transmission. J Med Virol 1992; 36: 28-31. 
44) Lott JA, Notte FS, Gretch R, Kott RS, Seett LB. Laboratory 
guide lines for screening, diagnosis, and monitoring hepatic 
injury.  In: DuFour DR (Editor). Laboratory Medicine Practice  
 
Guidelines. Washington (DC): National Academy of Clinical 
Biochemistry  2000: 21-23. 
45) Pawlotsky JM, Lonjon I, Hezode C, et al. Serological 
determination of hepatitis C virus genotype: comparison with a 
standardized genotyping assay. J Clin Microbiol 1997; 35:          
654-59. 
46) Clue P, Fang JW, Rouzier PR, et al.  Pegylated interferon alpha 
and preliminary efficacy, pharmacodynamics, safety and 
preliminary efficacy data. Hepatitis C intervention therapy group.  
Clin Pharmacol Ther 2000; 68: 556-67. 
47) Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic 
non-A, non-B hepatitis with recombinant human alpha 
interferon: a preliminary report. N Engl J Med 1986; 315:            
1575-578. 
48) DiBiscglie AM, Martin P, Kassianides J. Recombinant interferon 
alpha a therapy for chronic hepatitis C: a randomized, double-
blind, placebo controlled trial. N Engl J Med 1989; 321: 1506-
510. 
49) Cameron S, Jean AD, David PG, et al. Hepatitis B & C 
screening. In: Cameron  S, Jean  AD, David PG, et al (editors) 
Oxford Textbook of Clinical Nephrology, 1st ed. New York; 
Oxford University Press: 1992. P. 1285-1290. 
50) Sulkowski MS. HIV and hepatitis C virus. 37th Annual Meeting of 
the Infectious Diseases Society of America, Philadelphia 1999; 
Session 70: S 113. 
51) Sulkowski MS, Mast EE, Seeff LB. HCV infection as an 
opportunistic disease in persons with HIV. Clin Infect Dis 2000; 
30: 557-84. 
52) MciIntyre NE, Benhamou JP, Birche J, et al. Infection of the 
liver. In:  MciIntyre NE, Benhamou JP, Birche J, et al  (editors) 
Clinical Textbook of Hepatology. 2nd ed. Philadelphia; Churchill 
Livingstone: 1993: 1184-1186. 
53) Yuonne E. Hepatitis in renal unit. In: Yuonne E (editor) Hepatitis 
and its Control, 1st ed. London; Bailliere Tindall: 1977: 183. 
54) Choong  HL, Koh  L, Woo KT.  Anti -HCV seropositivity in long 
term haemodialysis patients.  Nephrol J 1992; 4: 91. 
55) Yoshida S, Takahashi C, Gaspar AM. Hepatitis C Virus in 
chronic haemodialysis patients with Non-A Non-B hepatitis.                       
Nephron  J  1992; 60: 150 – 53 . 
56) Schlipkoter  U, Roggendor  FM, Ernst  G.  Hepatitis C virus 
antibodies in haemodialysis patients. Lancet 1990; 336: 243-44.  
57) Zeldis  JB, Depner  TA, Kuramoto IK. The Prevalence of 
hepatitis C virus antibodies among   haemodialysis   patients.  
Ann Intern Med 1990; 112: 958 – 60 . 
58) Gilli  P, Morethetti  M, Sor ftritti  S. Anti- HCV positive patients in 
dialysis units.  Lancet  1990; 336: 243 – 44 . 
59) Abdel  Wahab MF, Karias Za, Kamel M, Abdel  Khaliq MK, 
Mabrouk  MA et al. High sero prevalence of hepatitis C infection 
among risk group in Egypt. Am J Trop Med Hyg 1994; 51(5): 
563 –67. 
60) El-Reshaid K , Kapoor M, Sugathan T, Al-Mufti S, Al-Hilali N.  
Hepatitis C virus infection in patients on maintenance dialysis in 
Kuwait: epidemiological profile and efficacy of prophylaxis. 
Saudi Kidney Dis Transplant 1995; 6(2):144– 50.    
61) Al- Shohaib SS, Abdelaal MA, Zawawi TH, Abbass FM,  
Shaheen FM.  The prevalence of Hepatitis C virus antibodies  
among hemodialysis patients in Jeddah area, Saudi Arabia. 
Saudi J Kidney Dis Transplant 1995; 6(2):128 – 31. 
62) Machida  J , Yamaguchi K, Ueda  S.   High incidence of  
hepatitis C virus antibodies in haemodialysis patients. Nephron 
1992; 60:117-18.       
63) Consolo F, Freni MA. Nosography and immunopathogenesis  of 
viral hepatitis. Nephron 1992; 61: 251– 54 . 
64) Dentico  P, VoIpe  A, Buongiorno  R.  Hepatitis C virus in 
haemodialysis patients. Nephron  1992; 61: 307 – 8.  
65) June ja M, Dubey AP, Kumari S, Pra Kash C, Mittal SK.   
Hepatitis B & C in multi transfused children. Trop Gastroenterol  
1998; 19:34 –6 . 
66) Niy H, Chang MH, Lue HC, HSU HY, Wang MJ  et al Post 
transfusion hepatitis C virus infection in children. J  pediatr 
1994; 124 (5): 709 – 13.  
67) Nagatchu T, Stroffolini T, Rapicetta M, Chionne P,  Lantum D  
et al. Sero prevalence of anti – HCV in  an urban child  
population : A pilot Survey in developing area, Cameroon. J 
Trop Med Hyg 1992; 95: 57–61.              
68) Tong MJ, El  Farra NS, Rei Kes AR, Corl S. Chronic viral 
hepatitis C & B.  N Eng J Med  1995 ; 332: 1463 – 465 . 
69) Roberts EA. Chronic hepatitis B and C in children. Saudi J  
Gastrol 1995; 1: 157 – 62 . 
70) Laver GM, Walker BD. Hepatitis C virus infection.   N Engl J 
Med  2001; 345 : 41- 52 . 
71) Souqiyyeh MZ, Shaheen FM, Huraib SO, Al Khadet AA. The 
annual incidence of seroconversion of antibodies to the  
hepatitis C virus in haemodialysis population in Saudi  Arabia. 
Saudi J kidney Dis Transplant 1995; 6(2): 167–73 .   
72) Rashad B. Renal replacement therapy in Egypt. Saudi J Kidney 
Dis Transplant 1997; 8(2): 152- 54. 
73) Fa Kunle Y,  Al- Mo Farren M, El- Karaman YW, Ezzat H, El- 
Edreees et al.  A prevalence of antibodies to hepatitis C virus in 
haemodialysis patients in Riyadh. Ann Saudi Med 1991; 11(5): 
504 – 6. 
74) Abul Kashem M,  Nuairat I, Mohamed M, Ramzy M, Nemma J.  
Hepatitis C virus Among haemodialysis patients in Najran: 
prevalence is more among multi centre visitors. Saudi J  Kidney 
Dis  Transplant 2003; 14 (2): 206 –11. 
75) Abdulla MY,  Al Jiffri S, Fadag RB, TawfiK  M,  Ghabrah F, 
Ibrahim A. Hepatitis C virus infection among  patients on 
haemodialysis in Jedddah: a single center experience. Saudi J 
Kidney Dis Transplant 2003; 14(1): 84 –9 .   
76) ElShalhat YI, Varma S , Bari MZ , Nawaz MS, Abdulrahman S 
et al. Hepatitis virus infection among  dialysis  patient, United  
Arab Emirates. Saudi J Kidney Dis Transplant 1995 ; 6(2): 157-
62. 
77) Saeed MG , Al  Harbi AS.  Hepatitis C virus sero -status in 
haemodialysis patients returning from holiday: another risk 
factor for HCV Transmission. Saudi J Kidney Dis Transplant 
2001; 12(1):14–20.   
78) Yamguchi  K , Nishimura  Y, Fu Kvo ka N. Hepatitis C virus 
antibodies in haemodialysis patients. Lancet 1990;                                                             
335: 1409-410. 
79) Mosconi  G, Desanctis  LB, Ste Foni S.  Epidemiology of 
hepatitis C in a population of haemodialysis patients. Nephron  
1992 ; 61: 298 –99. 
80) Alter JI, Coleman PJ, Alexander WJ. Importance of 
heterosexual activity in transmission of hepatitis B and  non- A  
non-B Hepatitis.  JAMA 1989; 262:1201–205 . 
81) Esteban  J, Esteban  R, Viladomiu  L.  Hepatitis C virus 
antibodies among risk group in Spain .Lancet 1989; 2: 294-96.    
82) Bernioh B , Allam M, Halepota A , Mohammed AO, PorKar J et 
al. Prevalence of hepatitis C virus antibodies in haemodialysis 
patients in Madina AL Munawarah . Saudi J Kidney Dis 
Transplant 1995; 6(2): 132 – 35. 
83) Lin  DY, Lin HH, Hunag CC, Liaw VF. High incidence of 
hepatitis C virus infection in Haemodialysis patients in Taiwan.  
Am J Kidney Dis 1993; 21(3): 288 – 91. 
84) Hardy NH, Sandronis Y, DnieIson T, Wilson WJ. Antibody to 
hepatitis C virus increases with time on haemodialysis. Clin 
Nephrol 1992; 38:44 –8.  
85) Abboud  O, Rashid A, Al Kaabi S. Hepatitis C virus infection in 
haemodialysis patients in Qatar. Saudi J Kidney Dis Transplant 
1995; 6(2): 151 – 53. 
86) Oliva JA, Maymo RM, Carrio J, Gado DEI, Mallatare JM. Late 
sero conversion of C virus markers in haemodialysis patients.  
Kidney Int 1993; 43: S153-56. 
87) Keur I , Schneeberger PM , Vander Graa FY , Vos J, Dij KWC, 
et al . Risk factor for HCV infection in two Haemodialysis  units 
in the Netherlands.   Neth J Med 1997; 50(3): 97–101.  
88) Shaheen FAM, Huraib So, Al-Rashed R.  Prevalence of 
hepatitis C antibodies among haemodialysis in Western 
province  of Saudi Arabia. Saudi J Kidney Dis Transplant 1995; 
6(2): 136-36. 
89) Muller GY, Zabaleta ME, Arminio A. Risk factor for dialysis - 
associated hepatitis C in Venezuela. Kidney Int 1992;  41:1055 
– 58.  
90) Ayoala EA, Huraibs, Ari FM.  Prevalence and  significant of 
antibodies to hepatitis C virus among Saudi  hemodialysis 
patients. J Med Virol 1991; 35: 155 – 59 .  
91) Saeed AA, Fairclough  D, Al- Addmawi AM. Hepatitis C virus in 
Saudi Arabia: a preliminary survey. Saudi Med J 1990; 11: 331 
–32 .  
92) Mitwalli A, Al- Mohya S, Al -WaKeel J. Hepatitis C in  chronic 
renal failure patients.  Am J Nephrol 1992; 12: 288 – 91. 
93) Donahre JG, Munzo A, Ness PM. The declining risk of post 
transfusion hepatitis C virus infection. N Eng I J Med 1992; 884 
–92. 
94) Berneih B, Allam M, Halepota A. Prevalence of hepatitis C virus 
antibodies in hemodialysis patients in Medina Al  Munawarah. 
Saudi Kidney Dis Tranplant Bull 1993; 4:573. 
95) Juneja M, Dubey AP, Kumaris, Prakash C, Mittal SK. Hepatitis 
B & C in multitransfused children. Trop Gastroenterol 1998; 
19:34 -6 
96) Al-Faleh FZ, Ayoola  EA, Al-Jeffry M. Prevalence of Antibody to 
hepatitis C virus among Saudi Arabian children. A community 
based study. Hepatology 1991; 14(2): 215–18. 
97) Khalifa AS, Mitchell BS, Watts DM, El -Samahy MH, El Sayed 
MH et al. Prevalence of hepatitis C virus antibody  in transfused 
Egyptian children.  AM  J Trop Med Hyg 1993; 49: 316- 21.  
98) Angyo IA, Ya Kub UAM. Lack of association between some risk 
factors and hepatitis B surface antigenaemia in children with 
sickle cell anaemia.  West Afr J Med 2001; 20(3): 214-18. 
99) Oguchi H, Miyasa Ka M, To Kunaga  S. Hepatitis virus  Infection 
and HCV in eleven Japanese hemodialysis units.  Clin Nephrol 
1992; 38: 36 – 43.    
100) Vasile A, Allegran V, Canciani D Forchi G, Mengozzi G.  
Prospective and retrospective assessment of clinical and 
laboratory parameters in maintenance haemodialysis patients 
with and without HCV antibodies. Nephron 1992; 61: 318-19.   
101) Pols Romeo R, Zins B. Hepatitis C virus RNA in Anti-HCV  
positive hemodialyzed patients: significance and therapeutic 
implications. Kidney Int 1993; 44:1097-100 .    
102) Ross EA. Abnormal Liver function test-1.  Semin Dial 1993; 
6:355 –58 . 
103) Alberti A, Morsica, Chemellol.  Hepatitis C viraemia and  liver 
disease in symptom-free individual with anti-HCV. Lancet 1992; 
340: 697 – 98.  
104) Brillanti S, Foli M, Goiani S, Masci C, Miglioli M. Persistent 
Hepatitis C viraemia without liver Disease. Lancet 1993; 
341:464 –65. 
105) Van Ness MM, Diehl AM. Is liver biopsy useful in the 
evaluation of patients with chronically elevated liver enzymes?  
Ann Intern Med 1989; 11: 473 – 78. 
106) Prieto M, Olaso V, Verdu C, Cordoba J, Gisbert C.  Does the 
healthy hepatitis C virus carrier state really exist? An analysis 
using polymerase chain reaction.  Hepatology 1995; 22 : 413–
17.  
107) Shaki Ao, Cnry-Catilena C,  Alter HJ, Haya Ship, Kleiner  DE 
et al.  Volunteer blood donors with antibody to Hepatitis C virus: 
clinical ,biochemical, virologic and histologic  features. Ann 
Intern Med 1995; 123: 330-37. 
108) Carameio C, Ortiz  A, Aguikera B, Porresj C, Navas  S et al. 
Liver disease patterns in haemodialysis patients  with antibodies 
to hepatitis C virus.  Am J Kidney Dis 1993; 22: 822-28.  
109) Pereira BJ, Natov SN, Bouthot BA, Murthx BV,  Ruthazer R et 
al. Effects of hepatitis C  infection and renal transplantation on 
survival in end-stage  renal disease. The New England Organ 
Bank Hepatitis C study  group. Kidney Int 1998; 53:1374-381. 
110) Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ,  Knddell RG 
et al. Long-term mortality after transfusion-associated non-A, 
non–B, hepatitis. The National Heat, Lung and Blood Institute 
Study Group. N Eng I J Med 1992; 327:1906-11.  
111) Matsumoto K, Nakamura T. Heparin functions as a 
hepatotrophic factors by inducing production of hepatocyte  
growth factor.  Biochem Biophys Res Commun 1996; 227: 455-
61 .  
112) Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C et 
al. Hemodialysis prevents liver disease caused by hepatitis C 
virus: role of hepatocyte growth factor. Kidney Int  1999; 56:  
2286 –291.  
113) Gibas A, Blewett DR, Schoen Feld DA, Dien Stag JL.  
Prevalence of viral Hepatitis in health workers in the  pre-  
hepatitis B vaccination era.  Am J Epidemiol 1992; 136: 603 - 
10. 
114) Al-Arrayed S. Renal replacement therapy in Bahrain. Saudi J  
Kidney Dis Transplant 1998; 9(4): 457 –58. 
115) Basem M, Othman M, Fawza S, Monem A. Prevalence of 
hepatitis C virus antibodies  among health care workers in 
Damascus, Syria. Saudi Med J 2001; 22(7): 603 –5.  
 
 
 
 
 
 
 
 
 
 
University of Khartoum 
Postgraduate Medical Studies Board 
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PREVALENCE OF HEPATITIS C VIRUS ANTIBODIES 
AMONG CHILDREN WITH 
CHRONIC RENAL FAILURE IN KHARTOUM STATE 
 
Date of interview:……………….. Serial No………………………… 
 
1- Personal data: 
Name………………………   Age:……………. 
Gender:                1) Male            2) Female 
Residence      
1) Urban                         2) Rural                    3) Suburban 
School grade 
1) Illiterate                       2) Primary                3) Secondary 
4) Post Secondary           5) Quran school (Khalwa) 
A-Father‘s Occupation  
1-Professionals               2-Civil servants ,Employees ,Merchants 
3-Skilled labourers         4-Uskilled labourers 
5-farmer’s,Shepherds     6-Unemployed 
Father’s  Education 
1-Illiterate                        2-Primary             3-Secondary 
4-Post Secondary             5-Quran School 
Mother’s  Education:   
1-Illiterate                         2-Primary                    3-Secondary 
4-Post secondary           5-Quran school 
 
 
2-Presenting compliant 
          Fever                                   1) Yes            2) No 
Anorexia                                 1) Yes             2) No 
Malaise                    1) Yes           2) No 
Abdominal pain                          1) Yes           2) No 
           Nausia                                        1) Yes           2) No 
           Vomiting                                   1) Yes           2) No 
           Haematemsis                          1) Yes           2) No 
           Diarrhea                         1) Yes           2) No 
           Constipation                               1) Yes           2) No 
           Pale stool                          1) Yes           2) No 
          Dark urine                                  1) Yes           2) No 
          Yellow sclera             1) Yes           2) No 
          Impaired sensorium                    1) Yes           2) No 
3- Past history: 
 P.H of  bilharsiasis                    1) Yes           2) No 
 P.H of jaundice                     1) Yes                    2) No 
If yes, when:                               
         1) Before dialysis       2) After dialysis 
Appearance of jaundice after transfusion  1) Yes         2) No 
P.H of contact with jaundice pt       1) Yes         2) No 
Does the child has hepatitis                  1) Yes         2) No 
If Yes what is the type …………………………….. 
Hepatitis            1) A          2) B         3) C        4) HIV        5) Others 
When  
1) Before dialysis           2) After dialysis             3) before transfusion   
Does the diagnosis of hepatitis confirm?   
1) Yes           2) No 
1) By history           2) Examination           3) Investigation 
Does the child received hepatitis B vaccine:  1) Yes         2) No 
Does the child treated for hepatitis      1) Yes         2) No 
Does the child have a result of ALT, AST    1) Yes         2) No 
1. ALT …………………………………………………. 
 2. AST …………………………………………………. 
P.H of hospitalization               1) Yes          2) No 
If Yes how frequent                   1) Once        2) Twice     3) More 
P.H of operation or procedure?  1) Yes         2) No 
Type of operation            
1) Abdominal                2) Cardiothoracic           3) Tonsillectomy                
4)Abscess drainage      5) Cautary marks       
6) Tattooing marks           7) Circumcision         8) Uvulectomy 
9) Tooth removal              10) Others         
P.H of blood transfusion    1) Yes         2) No 
If Yes, how many before dialysis  
1) Once    2) Twice    3) Trice    4) More 
How many after dialysis?              
1) Once    2) Twice    3) Trice    4) More 
Is it screened blood?                        1) Yes         2) No 
PH of reuse of injections  1) Yes         2) No 
4- Family history: 
F.H jaundice                                   1) Yes         2) No 
Hepatitis                                         1) Yes         2) No 
5-Social history  
Housing                 1) straw           2) mud          3) Bricks     4) Concrete 
 
 
 
Toilets:  
1) Communal latrine              2) Pit latrine (private)     
3) Pit latrine (shared)             4) Siphon  
5) Open space                         6) Others  
Electricity                      1) Yes              2) No  
Water supply  
1) Nile                   2) Traditional wells               3) Deep wells  
4) Piped in              5) Piped out    
6- Examination: 
Weight ………… kg                  Height………………………………….. 
Pallor                                          1) Yes           2) No 
Jaundice                                     1) Yes           2) No 
Temp.                                         1) Normal     2) Low    3) High 
Hepatomegaly                           1) Yes            2) No 
Rt. Hypochnodrium tenderness   1) Yes          2) No 
Splenomegaly                            1) Yes           2) No 
Lymph Node                              1) Yes          2) No 
Skin rash                                   1) Yes            2) No 
Bleeding Tendency                   1) Yes           2) No 
Tribal marks                             1) Yes           2) No 
Confusion                                  1) Yes           2) No 
Palmar Erythema                     1) Yes           2) No 
Spider Naevi                              1) Yes          2) No 
Cautry marks                            1) Yes          2) No 
7- Investigations:   
Liver enzymes  ALT……………                       
Hepatitis C by 3rd generation ELISA            1) +ve          2) -ve 
Hepatitis B                 1) +ve          2) –ve 
HIV                            1) +ve          2) –ve 
